EdCaN | The EdCaN Professional Development Framework …
Module Three – Core skills in cancer careOverviewThe aim of this module is to develop the ability of the beginning specialist cancer nurse to demonstrate competence in the core skills required to provide nursing care for people with cancer.Key conceptsThe key concepts associate with the core skills in cancer care are listed below:Supportive communication principles.Principles of a therapeutic relationship in cancer control.Applying comprehensive health assessment skills in cancer control.Identification and management of common Oncological Emergencies:Septic shockSuperior Vena Cava SyndromeTumor Lysis SyndromeMetastatic Spinal Cord CompressionHypercalcaemia Disseminated Intravascular Coagulation. Occupational Health and Safety concepts related to radiation and hazardous substances:Safety principles to limit exposure of staff to radiationHazards of cytotoxic medications and related wastePossible exposure routesControl measures related to cytotoxic medications and related wasteManagement of cytotoxic wasteManagement of a cytotoxic spillManagement of personal contamination.CVAD management:Clinical indications for CVAD insertion in people affected by cancer Types of CVADs used in a cancer care setting Common management principles for CVADs Possible complications related to CVADs.EdCaN Competency Assessment Tools or local competency/skills based assessment tools for:Radiation safetySafe handling of cytotoxic medication and related wasteManagement of CVADs.Learning activitiesAt times, you will have learning activities to complete. The questions will relate to the content you've just read or the video you've just watched.VideosYou will be prompted to access EdCaN videos throughout this module. Resource linksResource links may be included throughout the module. These links lead to interesting resources, articles or websites, and are designed to encourage you to explore other available information.Estimated time to complete80 hoursWorkplace learning requirementsThe EdCaN TSP is designed to support learning within the context of the policies, procedures and preferences of individual workplaces. Completion of this module and assessment of competence in specific practice areas needs to be supported by appropriately qualified educators, preceptors and clinicians in the participant’s practice setting. Opportunities for participants to undertake supervised practice of selected skills will be required. This support is designed to promote integration of knowledge to clinical practice. In conjunction with this learning module, it is recommended that the EdCaN Competency Assessment Tool for Antineoplastic Agent Administration is used to both facilitate the development and assessment of competence. It is anticipated that the minimum level achieved by the Beginning Specialist Cancer Nurse will be at the performance level “beginning competence as a specialist cancer nurse”. (Table 1) An alternative competency/skills based assessment tool may be used, but it is recommended that such a tool is mapped to the EdCaN resource to ensure that it reflects the nationally recognized standard of care with respect to administration of antineoplastic therapy.Table 1 EdCaN Competency Assessment Tool for Antineoplastic Agent Administration Band Level DescriptorsPerformance LevelInterpretationCOMPETENTEstablished competence as specialist cancer nurseComplies with legislation relevant to cancer care. Explains and justifies practice in accordance with local policy. Evaluates and appraises treatment orders. Is cognisant of individual’s specific condition, needs and preferences. Performs comprehensive and ongoing assessments. Has a sound knowledge underpinning antineoplastic therapy. Confident and independent in procedures. Efficient and dexterous technique demonstrated. Is able to manage changing scenarios. Documents and reports across the care continuum. Cognisant of organisation- wide/ global cancer control issues. Practices in a way that acknowledges the impact of cancer on the culture, dignity, values, beliefs of people affected by PETENTBeginning competence as specialist cancer nurseIdentifies and follows standard policy requirements with some specificity to chemotherapeutic agent or individual. Identifies and resolves unsafe situations. Nursing considerations limited to specific context but lack organisational/ global perspectives. Requires occasional prompts to carry out routine processes and practice. Evolving technique demonstrated.NOT YET COMPETENTKnowledge of local policy and rationales for practice limited to recall. Limited focus on task, individual or context. Requires continuous directions or prompts to carry out routine procedures. Accuracy and technique not dependable.ObjectivesOn completion of this module, you should be able to:Demonstrate principles of effective supportive communication to establish and maintain therapeutic relationships with people affected by cancer.Perform a comprehensive assessment to identify the impact of common disease and treatment effects on all domains of health experienced by people affected by cancer.Recognise and manage the common oncological emergencies that may be experienced by people affected by cancer.Describe potential hazards which impact on safe and effective care delivery in cancer care.Identify evidence based strategies for ensuring personal and professional safety when caring for people affected by cancer.Explain the theoretical concepts related to the common Central Venous Access Devices (CVADs) used in cancer care.Demonstrate competent and safe practice in the following core skills (as relevant to practice area):Radiation safetySafe handling of cytotoxicsManagement of CVADs.Supportive communication with people affected by cancerThe way in which a health professional and the treatment team relates to, and communicates with the person affected by cancer can significantly benefit their experience. Improvements in psychosocial adjustment, decision-making, treatment compliance and satisfaction with care have been reported. ADDIN EN.CITE <EndNote><Cite><Author>National Breast Cancer Centre</Author><Year>2003</Year><RecNum>643</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>643</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">643</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Breast Cancer Centre,</author><author>National Cancer Control Initiative,</author></authors></contributors><titles><title>Clinical practice guidelines for the psychosocial care of adults with cancer</title></titles><dates><year>2003</year></dates><pub-location>Camperdown</pub-location><publisher>National Breast Cancer Centre</publisher><urls><related-urls><url>.au/_files_nhmrc/file/publications/synopses/cp90.pdf </url></related-urls></urls></record></Cite></EndNote>1 There are evidence-based strategies that clinicians can use to improve their communication skills. Key person-centred communication skills include: ADDIN EN.CITE <EndNote><Cite><Author>Supportive Cancer Care Victoria</Author><Year>2011</Year><RecNum>1107</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>1107</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1107</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Supportive Cancer Care Victoria,</author></authors><secondary-authors><author>Department of Health,</author></secondary-authors></contributors><titles><title>Facilitator Manual: Supportive Care Screening Communication Skills Case Studies</title></titles><dates><year>2011</year></dates><pub-location>Victoria</pub-location><publisher>Supportive Cancer Care Victoria Project & Victorian Cancer Council</publisher><urls></urls></record></Cite></EndNote>2empathy – acknowledging and understanding a person’s feelings, both verbal and non-verbalactive listening – listening in an understanding way, both verbal and non-verbalactively encouraging questions and checking understanding – clarifying the message of the person affected by cancerasking open questions – encourages the person to talknot interruptingencouraging the presence of a support person – can help the person’s understanding, recall and/or satisfactionchecking the person’s preference for receiving information – to tailor the information for the person’s needsusing plain language – concise questions and comments without jargonnoticing non-verbal cues – picking up on a person’s body languagechecking that the person understands what you have said – explaining adequatelynormalising – can reassure the personsummarising – what has been said; checks that you have understood and invites the person to correct you or expand further.Two case study scenarios are provided below to stimulate reflection on therapeutic communication strategies which may be used when responding to anger and emotional cues.These resources were developed by Supportive Cancer Care Victoria and funded by the Cancer and Palliative Care Section of the Victorian State Government's Department of Health in support of Victoria's Supportive Care Policy.Scenario one: responding to angerAnger is a common reaction to a diagnosis of cancer and clinicians often care for people who are experiencing this emotion. Communication skills that will assist clinicians to confidently support people affected by cancer are: ADDIN EN.CITE <EndNote><Cite><Author>Supportive Cancer Care Victoria</Author><Year>2011</Year><RecNum>1107</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>1107</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1107</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Supportive Cancer Care Victoria,</author></authors><secondary-authors><author>Department of Health,</author></secondary-authors></contributors><titles><title>Facilitator Manual: Supportive Care Screening Communication Skills Case Studies</title></titles><dates><year>2011</year></dates><pub-location>Victoria</pub-location><publisher>Supportive Cancer Care Victoria Project & Victorian Cancer Council</publisher><urls></urls></record></Cite></EndNote>2staying calm and keeping an even tone of voiceactively listening and staying focused on the issuenot taking the anger personallynot being defensiveacknowledging the anger and exploring reasons for the angerapologizing if it is your faultlooking for underlying emotions and exploring further.While viewing this scene, look out for how the clinician uses these skills.Setting the scene George is 40 years old and was recently diagnosed with advanced pancreatic cancer and is waiting to meet the oncologist to discuss treatment options. He is married with three children (aged 12, 10, 7).Watch scenario 1. ADDIN EN.CITE <EndNote><Cite><Author>Supportive Cancer Care Victoria</Author><Year>2012</Year><RecNum>1407</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>1407</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1407</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Supportive Cancer Care Victoria,</author></authors></contributors><titles><title>Scenario one: responding to anger</title></titles><number>15.06.2012</number><dates><year>2012</year></dates><urls><related-urls><url> (Scene length - 4.30mins). Learning activitiesCompletedActivities Describe the verbal and non-verbal cues and behaviours demonstrated by George in the video.Discuss how the clinician used different communication skills within this scenario.Outline your response to the scenario in the event that the anger experienced by George escalated.Critically reflect upon your past experience with individuals demonstrating anger. Describe strengths in how you managed the situation effectively and areas you may have improved the interaction.Scenario two: responding to emotional cuesDistress and anxiety are common reactions to a diagnosis of cancer. Skills that assist the clinician to confidently support the person affected by cancer include: ADDIN EN.CITE <EndNote><Cite><Author>Supportive Cancer Care Victoria</Author><Year>2011</Year><RecNum>1107</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>1107</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1107</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Supportive Cancer Care Victoria,</author></authors><secondary-authors><author>Department of Health,</author></secondary-authors></contributors><titles><title>Facilitator Manual: Supportive Care Screening Communication Skills Case Studies</title></titles><dates><year>2011</year></dates><pub-location>Victoria</pub-location><publisher>Supportive Cancer Care Victoria Project & Victorian Cancer Council</publisher><urls></urls></record></Cite></EndNote>2 normalising feelingsallowing silenceusing minimal prompts such as yes, mmm, I see, etc.allowing the person to complete statements without interruptionmirroring the words the person uses and paraphrase responsessummarising key pointsaddressing issues that magnify anxietyreflective body language.Setting the sceneJoanne is 42 years old, and she has recently been diagnosed with breast cancer. She has had a wide local excision and sentinel node biopsy, followed by an axillary clearance due to positive lymph nodes. She has been told she will need radiotherapy and chemotherapy. Joanne lives with her partner Trish and Trish’s brother on a grain farm. She is a teacher at the local primary school.Watch scenario 2. ADDIN EN.CITE <EndNote><Cite><Author>Supportive Cancer Care Victoria</Author><Year>2012</Year><RecNum>1408</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>1408</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1408</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Supportive Cancer Care Victoria,</author></authors></contributors><titles><title>Scenario two: resonding to emotional cues</title></titles><number>15.06.2012</number><dates><year>2012</year></dates><urls><related-urls><url> (Scene length - 3.33mins).Learning activitiesCompletedActivities Identify the communication skills used by the clinician to explore Joanne’s concerns.Describe the verbal and non-verbal cues and behaviours demonstrated in the video.Discuss how the clinician used active listening.Critically reflect upon an experience you have had communicating with a person experiencing anxiety or an emotional disturbance. How did you respond effectively, and how could your response be improved?Comprehensive health assessment skills in cancer careAssessment forms an integral part of nursing. The priorities, needs and experiences of the person affected by cancer are a central focus of assessment and care planning. ADDIN EN.CITE <EndNote><Cite><Author>Aranda</Author><Year>2009</Year><RecNum>587</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>587</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">587</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author>Aranda, S.</author><author>Yates, P.</author></authors></contributors><titles><title>A national professional development framework for cancer nursing</title></titles><edition>2nd </edition><dates><year>2009</year></dates><pub-location>Canberra</pub-location><publisher>Cancer Australia, The National Cancer Nursing Education Project</publisher><urls></urls></record></Cite></EndNote>5 The process of assessment should be one of partnership between the care recipient and health professional. Assessment is a continuous process. Holistic assessment at key points forms part of this continuous process, and should supplement day-to-day appraisal of individual needs. ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url> Significant points along the individual’s journey may include: ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url> the time of diagnosis commencement of treatment completion of primary treatment plan each new episode of disease recurrence the point of recognition of incurability the beginning of the end of life the point at which dying is diagnosed any other time requested by the person affected by cancer any other time that a professional carer may judge necessary. Discretion should be applied to determine the most appropriate time to undertake an assessment; for example, immediately following diagnosis may be inappropriate, particularly if the individual is distressed. ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url> Assessment should include the following ‘domains’: ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url> background information and assessment preferences physical needs social and occupational needs psychological wellbeing spiritual wellbeinginformation needscarer’s needs. A tool such as the Patient Concerns Checklist may be used to support assessment of these domains. ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url> Figure 2: Overview of the Holistic Needs Assessment Process provides a guide to facilitate the assessment process throughout the cancer trajectory. ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url> 2: Overview of Holistic Needs Assessment Process(Source: Guidelines for Holistic Needs Assessment of Adult Cancer Patients, 2010 ADDIN EN.CITE <EndNote><Cite><Author>Psychology Support Working Group</Author><Year>2010</Year><RecNum>1106</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>1106</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1106</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>Psychology Support Working Group,</author></authors><secondary-authors><author>,</author></secondary-authors></contributors><titles><title>Guidelines for Holistic Needs Assessment of Adult Cancer Patients</title></titles><dates><year>2010</year></dates><publisher>Mersyeside and Cheshire Cancer Network</publisher><urls><related-urls><url>) Learning activitiesCompletedActivities Appraise the effectiveness of the assessment tool/s in your health care facility to holistically assess an individual’s plete and document an holistic health assessment for a person affected by cancer.For the person assessed in the above learning activity:Identify current needs and the assessment data that supports your decisionsIdentify future needs which may be anticipated and the assessment data that supports your decisions.Oncological emergenciesThe following conditions are examples of oncological emergencies: Febrile neutropaenia and sepsisSuperior vena cava syndromeTumour lysis syndromeSpinal cord compressionDisseminated intravascular coagulation HypercalcaemiaFebrile neutropaenia and sepsisAetiology and contributing factorsFebrile neutropaenia (FN) and sepsis are distinct phenomena but are often discussed in conjunction with each other. FN is present in individuals with a temperature above 38°C for at least one hour and a neutrophil count of less than 0.5 x109, or 1.0 x109 with a predictable decline to 0.5 x109. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DYW5jZXIgSW5zdGl0dXRlIE5ldyBTb3V0aCBXYWxlczwv
QXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+PFJlY051bT4zNTE8L1JlY051bT48RGlzcGxheVRleHQ+
PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij43LTk8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29y
ZD48cmVjLW51bWJlcj4zNTE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i
IGRiLWlkPSIycjB4czA5cHc5c2VhZWUwZGQ3eHR6NW1wdzkweDJ0MnJhcGUiPjM1MTwva2V5Pjwv
Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJXZWIgUGFnZSI+MTI8L3JlZi10eXBlPjxjb250
cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5DYW5jZXIgSW5zdGl0dXRlIE5ldyBTb3V0aCBXYWxl
cyw8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+SW1tZWRp
YXRlIG1hbmFnZW1lbnQgb2YgIG5ldXRyb3BhZW5pYyBmZXZlcjwvdGl0bGU+PC90aXRsZXM+PG51
bWJlcj4xMi4wNS4yMDExPC9udW1iZXI+PGRhdGVzPjx5ZWFyPjIwMTA8L3llYXI+PC9kYXRlcz48
cHVibGlzaGVyPkNhbmNlciBJbnN0aXR1dGUgb2YgTlNXPC9wdWJsaXNoZXI+PHVybHM+PHJlbGF0
ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3LmV2aXEub3JnLmF1L1Byb3RvY29sL3RhYmlkLzY2L2lk
LzEyMy9EZWZhdWx0LmFzcHg8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9D
aXRlPjxDaXRlPjxBdXRob3I+TmF0aW9uYWwgQ29tcHJlaGVuc2l2ZSBDYW5jZXIgTmV0d29yayAo
TkNDTik8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxSZWNOdW0+NzwvUmVjTnVtPjxyZWNvcmQ+
PHJlYy1udW1iZXI+NzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt
aWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4dHo1bXB3OTB4MnQycmFwZSI+Nzwva2V5PjwvZm9yZWln
bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJXZWIgUGFnZSI+MTI8L3JlZi10eXBlPjxjb250cmlidXRv
cnM+PGF1dGhvcnM+PGF1dGhvcj5OYXRpb25hbCBDb21wcmVoZW5zaXZlIENhbmNlciBOZXR3b3Jr
IChOQ0NOKSw8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+
TkNDTiBDbGluaWNhbCBQcmFjdGljZSBHdWlkZWxpbmVzIGluIE9uY29sb2d5OiBwcmV2ZW50aW9u
IGFuZCB0cmVhdG1lbnQgb2YgY2FuY2VyLXJlbGF0ZWQgaW5mZWN0aW9ucywgdmVyc2lvbiAyPC90
aXRsZT48L3RpdGxlcz48bnVtYmVyPjE3LjAyLjIwMTI8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAx
MTwveWVhcj48L2RhdGVzPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jY24u
b3JnL3Byb2Zlc3Npb25hbHMvcGh5c2ljaWFuX2dscy9wZGYvaW5mZWN0aW9ucy5wZGY8L3VybD48
L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TmF0aW9u
YWwgQ29tcHJlaGVuc2l2ZSBDYW5jZXIgTmV0d29yayAoTkNDTik8L0F1dGhvcj48WWVhcj4yMDEx
PC9ZZWFyPjxSZWNOdW0+NzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NzwvcmVjLW51bWJl
cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4
dHo1bXB3OTB4MnQycmFwZSI+Nzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJX
ZWIgUGFnZSI+MTI8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OYXRp
b25hbCBDb21wcmVoZW5zaXZlIENhbmNlciBOZXR3b3JrIChOQ0NOKSw8L2F1dGhvcj48L2F1dGhv
cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+TkNDTiBDbGluaWNhbCBQcmFjdGljZSBH
dWlkZWxpbmVzIGluIE9uY29sb2d5OiBwcmV2ZW50aW9uIGFuZCB0cmVhdG1lbnQgb2YgY2FuY2Vy
LXJlbGF0ZWQgaW5mZWN0aW9ucywgdmVyc2lvbiAyPC90aXRsZT48L3RpdGxlcz48bnVtYmVyPjE3
LjAyLjIwMTI8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAxMTwveWVhcj48L2RhdGVzPjx1cmxzPjxy
ZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jY24ub3JnL3Byb2Zlc3Npb25hbHMvcGh5c2lj
aWFuX2dscy9wZGYvaW5mZWN0aW9ucy5wZGY8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9y
ZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+UmF0aGFuYXlha2U8L0F1dGhvcj48WWVhcj4yMDEx
PC9ZZWFyPjxSZWNOdW0+MzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MzwvcmVjLW51bWJl
cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4
dHo1bXB3OTB4MnQycmFwZSI+Mzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJQ
YW1waGxldCI+MjQ8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5SYXRo
YW5heWFrZSwgVGhhcmFuZ2E8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxl
cz48dGl0bGU+RXZpZGVuY2Ugc3VtbWFyeTogaW5mZWN0aW9uIG1hbmFnZW1lbnQ6IGZlYnJpbGUg
bmV1dHJvcGFlbmlhPC90aXRsZT48L3RpdGxlcz48ZGF0ZXM+PHllYXI+MjAxMTwveWVhcj48L2Rh
dGVzPjxwdWItbG9jYXRpb24+QWRlbGFpZGU8L3B1Yi1sb2NhdGlvbj48cHVibGlzaGVyPkpvYW5u
YSBCcmlnZ3MgSW5zdGl0dXRlPC9wdWJsaXNoZXI+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0
dHA6Ly9jb25uZWN0LmpiaWNvbm5lY3RwbHVzLm9yZy9WaWV3RG9jdW1lbnQuYXNweD8wPTQ3OTc8
L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DYW5jZXIgSW5zdGl0dXRlIE5ldyBTb3V0aCBXYWxlczwv
QXV0aG9yPjxZZWFyPjIwMTA8L1llYXI+PFJlY051bT4zNTE8L1JlY051bT48RGlzcGxheVRleHQ+
PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij43LTk8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29y
ZD48cmVjLW51bWJlcj4zNTE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i
IGRiLWlkPSIycjB4czA5cHc5c2VhZWUwZGQ3eHR6NW1wdzkweDJ0MnJhcGUiPjM1MTwva2V5Pjwv
Zm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJXZWIgUGFnZSI+MTI8L3JlZi10eXBlPjxjb250
cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5DYW5jZXIgSW5zdGl0dXRlIE5ldyBTb3V0aCBXYWxl
cyw8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+SW1tZWRp
YXRlIG1hbmFnZW1lbnQgb2YgIG5ldXRyb3BhZW5pYyBmZXZlcjwvdGl0bGU+PC90aXRsZXM+PG51
bWJlcj4xMi4wNS4yMDExPC9udW1iZXI+PGRhdGVzPjx5ZWFyPjIwMTA8L3llYXI+PC9kYXRlcz48
cHVibGlzaGVyPkNhbmNlciBJbnN0aXR1dGUgb2YgTlNXPC9wdWJsaXNoZXI+PHVybHM+PHJlbGF0
ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3LmV2aXEub3JnLmF1L1Byb3RvY29sL3RhYmlkLzY2L2lk
LzEyMy9EZWZhdWx0LmFzcHg8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9D
aXRlPjxDaXRlPjxBdXRob3I+TmF0aW9uYWwgQ29tcHJlaGVuc2l2ZSBDYW5jZXIgTmV0d29yayAo
TkNDTik8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxSZWNOdW0+NzwvUmVjTnVtPjxyZWNvcmQ+
PHJlYy1udW1iZXI+NzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt
aWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4dHo1bXB3OTB4MnQycmFwZSI+Nzwva2V5PjwvZm9yZWln
bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJXZWIgUGFnZSI+MTI8L3JlZi10eXBlPjxjb250cmlidXRv
cnM+PGF1dGhvcnM+PGF1dGhvcj5OYXRpb25hbCBDb21wcmVoZW5zaXZlIENhbmNlciBOZXR3b3Jr
IChOQ0NOKSw8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+
TkNDTiBDbGluaWNhbCBQcmFjdGljZSBHdWlkZWxpbmVzIGluIE9uY29sb2d5OiBwcmV2ZW50aW9u
IGFuZCB0cmVhdG1lbnQgb2YgY2FuY2VyLXJlbGF0ZWQgaW5mZWN0aW9ucywgdmVyc2lvbiAyPC90
aXRsZT48L3RpdGxlcz48bnVtYmVyPjE3LjAyLjIwMTI8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAx
MTwveWVhcj48L2RhdGVzPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jY24u
b3JnL3Byb2Zlc3Npb25hbHMvcGh5c2ljaWFuX2dscy9wZGYvaW5mZWN0aW9ucy5wZGY8L3VybD48
L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+TmF0aW9u
YWwgQ29tcHJlaGVuc2l2ZSBDYW5jZXIgTmV0d29yayAoTkNDTik8L0F1dGhvcj48WWVhcj4yMDEx
PC9ZZWFyPjxSZWNOdW0+NzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+NzwvcmVjLW51bWJl
cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4
dHo1bXB3OTB4MnQycmFwZSI+Nzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJX
ZWIgUGFnZSI+MTI8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5OYXRp
b25hbCBDb21wcmVoZW5zaXZlIENhbmNlciBOZXR3b3JrIChOQ0NOKSw8L2F1dGhvcj48L2F1dGhv
cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+TkNDTiBDbGluaWNhbCBQcmFjdGljZSBH
dWlkZWxpbmVzIGluIE9uY29sb2d5OiBwcmV2ZW50aW9uIGFuZCB0cmVhdG1lbnQgb2YgY2FuY2Vy
LXJlbGF0ZWQgaW5mZWN0aW9ucywgdmVyc2lvbiAyPC90aXRsZT48L3RpdGxlcz48bnVtYmVyPjE3
LjAyLjIwMTI8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAxMTwveWVhcj48L2RhdGVzPjx1cmxzPjxy
ZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jY24ub3JnL3Byb2Zlc3Npb25hbHMvcGh5c2lj
aWFuX2dscy9wZGYvaW5mZWN0aW9ucy5wZGY8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9y
ZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+UmF0aGFuYXlha2U8L0F1dGhvcj48WWVhcj4yMDEx
PC9ZZWFyPjxSZWNOdW0+MzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MzwvcmVjLW51bWJl
cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4
dHo1bXB3OTB4MnQycmFwZSI+Mzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJQ
YW1waGxldCI+MjQ8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5SYXRo
YW5heWFrZSwgVGhhcmFuZ2E8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxl
cz48dGl0bGU+RXZpZGVuY2Ugc3VtbWFyeTogaW5mZWN0aW9uIG1hbmFnZW1lbnQ6IGZlYnJpbGUg
bmV1dHJvcGFlbmlhPC90aXRsZT48L3RpdGxlcz48ZGF0ZXM+PHllYXI+MjAxMTwveWVhcj48L2Rh
dGVzPjxwdWItbG9jYXRpb24+QWRlbGFpZGU8L3B1Yi1sb2NhdGlvbj48cHVibGlzaGVyPkpvYW5u
YSBCcmlnZ3MgSW5zdGl0dXRlPC9wdWJsaXNoZXI+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0
dHA6Ly9jb25uZWN0LmpiaWNvbm5lY3RwbHVzLm9yZy9WaWV3RG9jdW1lbnQuYXNweD8wPTQ3OTc8
L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=
ADDIN EN.CITE.DATA 7-9 In people receiving treatment for cancer, neutropaenia may be the result of treatment with certain antineoplastic agents or the use of radiotherapy where marrow-producing bones (such as the long limb bones, the sternum and the cranium) fall into the field of radiation. ADDIN EN.CITE <EndNote><Cite><Author>National Comprehensive Cancer Network (NCCN)</Author><Year>2011</Year><RecNum>7</RecNum><DisplayText><style face="superscript">8, 10</style></DisplayText><record><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">7</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>National Comprehensive Cancer Network (NCCN),</author></authors></contributors><titles><title>NCCN Clinical Practice Guidelines in Oncology: prevention and treatment of cancer-related infections, version 2</title></titles><number>17.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">438</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Harnett, Paul R.</author></authors><secondary-authors><author>Bishop, James</author></secondary-authors></contributors><titles><title>Oncological emergencies</title><secondary-title>Cancer facts: a concise oncology text</secondary-title></titles><dates><year>1999</year></dates><pub-location>London</pub-location><publisher>CRC Press</publisher><urls></urls></record></Cite></EndNote>8, 10 Other risk factors for FN include: ADDIN EN.CITE <EndNote><Cite><Author>Lyman</Author><Year>2005</Year><RecNum>354</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>354</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lyman, Gary H.</author><author>Lyman, Christopher H.</author><author>Agboola, Olayemi</author><author>for the Anc Study Group,</author></authors></contributors><titles><title>Risk Models for Predicting Chemotherapy-Induced Neutropenia</title><secondary-title>Oncologist</secondary-title></titles><periodical><full-title>Oncologist</full-title></periodical><pages>427-437</pages><volume>10</volume><number>6</number><dates><year>2005</year></dates><urls><related-urls><url> agepoor performance statusthe presence of co-morbidities like renal and heart disease. FN can indicate infection and rapidly progress to severe sepsis if left untreated. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> is defined as an infection that causes systemic symptoms. ADDIN EN.CITE <EndNote><Cite><Author>Daniels</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Daniels, Ron</author></authors></contributors><titles><title>Defining sepsis, severe sepsis and septic shock</title><secondary-title>NHS Evidence: Emergency and urgent care</secondary-title></titles><number>24.03.2011</number><dates><year>2009</year></dates><publisher>NHS</publisher><urls><related-urls><url> These symptoms are caused by the body’s ‘Systemic Inflammatory Response Syndrome’, or SIRS ADDIN EN.CITE <EndNote><Cite><Author>Daniels</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">13, 14</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Daniels, Ron</author></authors></contributors><titles><title>Defining sepsis, severe sepsis and septic shock</title><secondary-title>NHS Evidence: Emergency and urgent care</secondary-title></titles><number>24.03.2011</number><dates><year>2009</year></dates><publisher>NHS</publisher><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">2</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Levy, Michael M.</author></authors><secondary-authors><author>Daniels, Ron</author><author>Nutbeam, Tim</author></secondary-authors></contributors><titles><title>Introduction</title><secondary-title>ABC of Sepsis,</secondary-title></titles><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>13, 14, and may include two or more of the following: ADDIN EN.CITE <EndNote><Cite><Author>Daniels</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Daniels, Ron</author></authors></contributors><titles><title>Defining sepsis, severe sepsis and septic shock</title><secondary-title>NHS Evidence: Emergency and urgent care</secondary-title></titles><number>24.03.2011</number><dates><year>2009</year></dates><publisher>NHS</publisher><urls><related-urls><url> abnormal temperature, either < 36°C or >38°Cheart rate of > 90 beats per minuterespiratory rate of > 20 breaths per minuteacutely altered mental state.Severe sepsis is defined as sepsis with the addition of sepsis-induced organ dysfunction or tissue hypoperfusion. ADDIN EN.CITE <EndNote><Cite><Author>Dellinger</Author><Year>2008</Year><RecNum>5</RecNum><DisplayText><style face="superscript">15</style></DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dellinger, R. Phillip</author><author>Levy, Mitchell M.</author><author>Carlet, Jean M.</author><author>Bion, Julian</author><author>Parker, Margaret M.</author><author>Jaeschke, Roman</author><author>et al</author></authors></contributors><titles><title>Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008</title><secondary-title>Critical Care Medicine</secondary-title></titles><periodical><full-title>Critical Care Medicine</full-title></periodical><pages>296-327</pages><volume>36</volume><dates><year>2008</year></dates><urls></urls></record></Cite></EndNote>15 Septic shock occurs when sepsis-induced hypotension occurs despite adequate treatment. ADDIN EN.CITE <EndNote><Cite><Author>Levy</Author><Year>2009</Year><RecNum>2</RecNum><DisplayText><style face="superscript">14</style></DisplayText><record><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">2</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Levy, Michael M.</author></authors><secondary-authors><author>Daniels, Ron</author><author>Nutbeam, Tim</author></secondary-authors></contributors><titles><title>Introduction</title><secondary-title>ABC of Sepsis,</secondary-title></titles><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>14 If left untreated, severe sepsis can result in death within hours. ADDIN EN.CITE <EndNote><Cite><Author>Harnett</Author><Year>1999</Year><RecNum>438</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>438</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">438</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Harnett, Paul R.</author></authors><secondary-authors><author>Bishop, James</author></secondary-authors></contributors><titles><title>Oncological emergencies</title><secondary-title>Cancer facts: a concise oncology text</secondary-title></titles><dates><year>1999</year></dates><pub-location>London</pub-location><publisher>CRC Press</publisher><urls></urls></record></Cite></EndNote>10Assessment and monitoringIn individuals affected by cancer and its treatments, the inflammatory response may be diminished or even absent. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> This means that for this group, the signs of SIRS may not necessarily be present to indicate sepsis ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url>, and so astute nursing assessment and prompt management is vital.Subtle signs that may indicate infection in the person with cancer may include an increase in heart rate, warm flushed skin, slight decreases in blood pressure and urine output, and slight changes in mental status. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> A septic workup is performed when an individual is suspected of suffering from either FN or sepsis. This process involves a number of tests including: ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> cultures; one set of aerobic and anaerobic bottles should be taken from each lumen of any CVAD in situ, and one set taken peripherallyfull blood countelectrolytes and liver function testsurine specimenswab of any CVAD exit siteswab of any other suspicious woundsif clinically indicated, faeces and sputum specimensa chest x-ray.Resource linkThe eviQ website ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><RecNum>349</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">349</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>eviQ Home</title></titles><number>12.05.2011</number><dates></dates><publisher>Cancer Institute NSW</publisher><urls><related-urls><url> contains a resource on the Immediate management of neutropaenic fever ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> (This is a free resource, but you must register and log in to access).Learning activitiesCompletedActivities List the key signs and symptoms of SIRS and sepsis in a person with cancer.Review local policy and procedures and outline requirements for a full septic screen for a person with febrile neutropaenia.Recommended intervention strategiesPreventionSepsis in people with cancer is generally caused by gram-negative bacteria like Escherichia coli and Pseudomonas sp. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> In most cases, these bacteria are part of the person’s normal flora. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> Good hand washing and general personal hygiene practices remain key nursing strategies to prevent FN and sepsis. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> People at risk of developing FN or sepsis must also receive education on:6,9signs and symptoms of FN and sepsis actions that should be taken in the event of these signs or symptoms developing ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> potential exposure to infectious sources ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> at which people receiving treatment for cancer will be at their greatest risk of infection.ManagementAll persons receiving treatment for cancer who present with a fever should be managed as if they are neutropaenic, without waiting for laboratory confirmation of their neutrophil count. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> The key nursing priorities when dealing with FN or sepsis is prompt assessment using a septic workup as per local policy and procedures. People with symptoms of sepsis should receive antibiotics within 30 minutes of presentation. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> For those with suspected or confirmed FN that has not yet progressed to sepsis, antibiotic therapy should, if possible, commence within one hour of presentation. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> Ideally, blood cultures should be collected prior to the commencement of antibiotics, in order to better identify the causative infectious agent. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> therapy should be based on the clinical findings of the tests performed ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> and may also include the administration of intravenous fluid, blood products, oxygen, and/ or vasopressors. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> Individuals experiencing altered mental status must also be closely monitored to ensure safety. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> supportive management strategies undertaken by nurses include: ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> the person’s response to therapy by checking vital signs regularly reviewing test results as appropriateassessing for signs and symptoms of septic shocksupportive management of feverprovision of information and supportive care to reduce concerns and psychological distress.Resource linksThe eviQ website ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><RecNum>349</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">349</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>eviQ Home</title></titles><number>12.05.2011</number><dates></dates><publisher>Cancer Institute NSW</publisher><urls><related-urls><url> contains a resource on the Immediate management of neutropaenic fever. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Institute New South Wales</Author><Year>2010</Year><RecNum>351</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">351</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Institute New South Wales,</author></authors></contributors><titles><title>Immediate management of neutropaenic fever</title></titles><number>12.05.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute of NSW</publisher><urls><related-urls><url> This includes a table detailing the antibiotics that should be used to treat FN and sepsis. (This is a free resource, but you must register and log in to access).You may also find the NCCN Guidelines on The prevention and treatment of cancer-related infections ADDIN EN.CITE <EndNote><Cite><Author>National Comprehensive Cancer Network (NCCN)</Author><Year>2011</Year><RecNum>7</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">7</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>National Comprehensive Cancer Network (NCCN),</author></authors></contributors><titles><title>NCCN Clinical Practice Guidelines in Oncology: prevention and treatment of cancer-related infections, version 2</title></titles><number>17.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> ) helpful. (This is a free resource, but you must register and log in to access).Learning activitiesCompletedActivities Develop a care plan for a person with febrile neutropaenia. Discuss the rationales for nursing interventions with your mentor / facilitator.Discuss the core components of an education program for the person affected by cancer to reduce the risk of sepsis.Tumour lysis syndromeAetiology and contributing factorsTumour lysis syndrome (TLS) is caused by the death, or lysis, of a large number of tumour cells. ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><Year>2010</Year><RecNum>447</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">447</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author></authors></contributors><titles><title>Tumour lysis syndrome, risk assessment, prophylaxis</title></titles><number>02.06.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute New South Wales</publisher><urls><related-urls><url> Tumour lysis can occur either spontaneously or in response to anti-cancer treatment. ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> When cancer cells die, they release potassium, phosphorous, cytokines and nucleic acids (which are metabolised into uric acid) into the bloodstream. ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> TLS occurs when more of these substances are released during cell lysis than the body’s homeostatic mechanisms can manage.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2dhbjwvQXV0aG9yPjxZZWFyPjE5OTggPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2dhbjwvQXV0aG9yPjxZZWFyPjE5OTggPC9ZZWFyPjxS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ADDIN EN.CITE.DATA 16, 19 This can cause the following metabolic imbalances: ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> metabolic disturbances can lead to clinical toxicities including renal insufficiency, cardiac arrhythmias, seizures, and death due to multi-organ failure. ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> Cytokine release can also cause Systemic Inflammatory Response Syndrome (SIRS) and multi-organ failure. ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> TLS occurs most commonly in haematologic malignancies such as leukaemias and lymphomas, and is less common in people with solid tumours. ADDIN EN.CITE <EndNote><Cite><Author>Ezzone</Author><Year>1999</Year><RecNum>442</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ezzone, Susan A.</author></authors></contributors><titles><title>Tumor lysis syndrome</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><volume>15</volume><number>3</number><section>202-208</section><dates><year>1999</year></dates><urls></urls></record></Cite></EndNote>20 Tumour lysis can occur in response to antineoplastic therapy, but can also be the result of high doses of steroids, surgery, radiation, molecular and biological targeted therapy, and endocrine therapy. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16, 21</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">443</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Doane, Lois</author></authors></contributors><titles><title>Overview of tumour lysis syndrome</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><volume>18</volume><number>3</number><section>2-5</section><dates><year>2002</year></dates><urls></urls></record></Cite></EndNote>16, 21 It can also occur spontaneously. ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><Year>2010</Year><RecNum>447</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">447</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author></authors></contributors><titles><title>Tumour lysis syndrome, risk assessment, prophylaxis</title></titles><number>02.06.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute New South Wales</publisher><urls><related-urls><url> has been reported to occur most commonly within the first 24 to 48 hours after the initiation of treatment for cancer, and may persist for five to seven days. ADDIN EN.CITE <EndNote><Cite><Author>Ezzone</Author><Year>1999</Year><RecNum>442</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ezzone, Susan A.</author></authors></contributors><titles><title>Tumor lysis syndrome</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><volume>15</volume><number>3</number><section>202-208</section><dates><year>1999</year></dates><urls></urls></record></Cite></EndNote>20 Late development of TLS may also occur, with the onset of signs and symptoms occurring up to four days post treatment. ADDIN EN.CITE <EndNote><Cite><Author>Ezzone</Author><Year>1999</Year><RecNum>442</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ezzone, Susan A.</author></authors></contributors><titles><title>Tumor lysis syndrome</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><volume>15</volume><number>3</number><section>202-208</section><dates><year>1999</year></dates><urls></urls></record></Cite></EndNote>20Learning activitiesCompletedActivities Summarise the pathophysiology of the development of TLS.For the metabolic imbalances associated with TLS, outline:the normal ranges of these electrolytesthe signs and symptoms of each metabolic imbalance.Assessment and monitoringAstute clinical assessment can help to proactively identify the persons at risk for the development of TLS. Nurses also has an important role in the administration of prescribed prophylactic therapy, aimed at preventing TLS from occurring. ADDIN EN.CITE <EndNote><Cite><Author>Doane</Author><Year>2002</Year><RecNum>443</RecNum><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>443</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">443</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Doane, Lois</author></authors></contributors><titles><title>Overview of tumour lysis syndrome</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><volume>18</volume><number>3</number><section>2-5</section><dates><year>2002</year></dates><urls></urls></record></Cite></EndNote>21 Individuals at risk of TLS must also undergo frequent assessment, focusing on the presence of the metabolic abnormalities discussed above and clinical symptoms of TLS.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib3dhcmQ8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib3dhcmQ8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS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ADDIN EN.CITE.DATA 19-21Clinical symptoms of TLS include: ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> dysrhythmias, which may be indicated by an abnormal pulse rate, irregular pulse, or abnormal blood pressureneuromuscular irritability, which may be evidenced by tetany, paresthesias, or muscle twitchingoliguria, defined as an average urine output of less than 0.5mL/kg/hr for 6 hours or more.Learning activitiesCompletedActivities [copy activities to your notebook]Discuss the difference between laboratory TLS and clinical TLS, and how you would monitor for both.Describe some common psychosocial concerns and needs that people with TLS may experience. (You may find this article helpful: Psychosocial care for patients and their families is integral to supportive care in cancer: MASCC position statement).Recommended intervention strategiesPreventionThe best management of TLS is prevention of its occurrence. ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><Year>2010</Year><RecNum>447</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">447</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author></authors></contributors><titles><title>Tumour lysis syndrome, risk assessment, prophylaxis</title></titles><number>02.06.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute New South Wales</publisher><urls><related-urls><url> Treatment to prevent TLS may be based around a risk assessment identifying whether a person is at low, intermediate, or high risk of TLS. This treatment is outlined below: ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><Year>2010</Year><RecNum>447</RecNum><DisplayText><style face="superscript">18, 19</style></DisplayText><record><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">447</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author></authors></contributors><titles><title>Tumour lysis syndrome, risk assessment, prophylaxis</title></titles><number>02.06.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute New South Wales</publisher><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url>, 19Low risk: Intravenous fluids, allopurinol, daily electrolyte monitoring. Intermediate risk: Intravenous fluids, purine analogues or a recombinant urate oxidase enzyme, electrolyte monitoring every 8-12 hours.High risk: Intravenous fluids, purine analogues or a recombinant urate oxidase enzyme, cardiac monitoring, electrolyte monitoring every 6-8 hours.This treatment should be commenced at least 48 hours before antineoplastic therapy. ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><Year>2010</Year><RecNum>447</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">447</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author></authors></contributors><titles><title>Tumour lysis syndrome, risk assessment, prophylaxis</title></titles><number>02.06.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute New South Wales</publisher><urls><related-urls><url> persons with established TLS, nursing management may include continuous cardiac monitoring, electrolyte monitoring every 4-6 hours, and the administration of intravenous fluids and rasburicase. ADDIN EN.CITE <EndNote><Cite><Author>Howard</Author><Year>2011</Year><RecNum>441</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Howard, Scott C.</author><author>Jones, Deborah P.</author><author>Pui, Ching-Hon</author></authors></contributors><titles><title>The Tumor Lysis Syndrome</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>1844-1854</pages><volume>364</volume><number>19</number><dates><year>2011</year></dates><urls><related-urls><url> Learning activityCompletedActivityOutline key aspects in the nursing plan for the newly diagnosed individual at risk of TLS prior to and post commencement of treatment. Metastatic spinal cord compressionAetiology and contributing factorsMetastases to the spinal column occur in three to five percent of all people with cancer. ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> Metastatic spinal cord compression (MSCC) occurs when these metastases cause vertebral body collapse, or direct tumour growth causes compression of the spinal cord or cauda equina. ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> MSCC most commonly occurs in individuals with breast, prostate, or lung cancer, with these three cancers accounting for more than 50% of the MSCC cases seen. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12, 22</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url>, 22 The risk of experiencing MSCC increases the longer someone has cancer. ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> This means that as more people with cancer are surviving for longer, the incidence of MSCC may be increasing. ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> presenting symptoms of MSCC include:PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYWxqaTwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYWxqaTwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl
Y051bT4zNTI8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4x
MiwgMjIsIDIzPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MzUyPC9y
ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMnIweHMwOXB3OXNl
YWVlMGRkN3h0ejVtcHc5MHgydDJyYXBlIj4zNTI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5
cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0
aG9ycz48YXV0aG9yPldhbGppLCBOPC9hdXRob3I+PGF1dGhvcj5DaGFuLCBBIEs8L2F1dGhvcj48
YXV0aG9yPlBlYWtlLCBEIFI8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxl
cz48dGl0bGU+Q29tbW9uIGFjdXRlIG9uY29sb2dpY2FsIGVtZXJnZW5jaWVzOiBkaWFnbm9zaXMs
IGludmVzdGlnYXRpb24gYW5kIG1hbmFnZW1lbnQ8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+UG9z
dGdyYWR1YXRlIE1lZGljYWwgSm91cm5hbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJp
b2RpY2FsPjxmdWxsLXRpdGxlPlBvc3RncmFkdWF0ZSBNZWRpY2FsIEpvdXJuYWw8L2Z1bGwtdGl0
bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz40MTgtNDI3PC9wYWdlcz48dm9sdW1lPjg0PC92b2x1bWU+
PG51bWJlcj45OTQ8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAwODwveWVhcj48L2RhdGVzPjx1cmxz
PjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vcG1qLmJtai5jb20vY29udGVudC84NC85OTQvNDE4
LmFic3RyYWN0PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNl
LW51bT4xMC4xMTM2L3BnbWouMjAwNy4wNjcwMzM8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv
cmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPk5hdGlvbmFsIEluc3RpdHV0ZSBmb3IgSGVhbHRo
IGFuZCBDbGluaWNhbCBFeGNlbGxlbmNlIChOSUNFKTwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+
PFJlY051bT40NDY8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ0NjwvcmVjLW51bWJlcj48
Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlwdzlzZWFlZTBkZDd4dHo1
bXB3OTB4MnQycmFwZSI+NDQ2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikdv
dmVybm1lbnQgRG9jdW1lbnQiPjQ2PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh
dXRob3I+TmF0aW9uYWwgSW5zdGl0dXRlIGZvciBIZWFsdGggYW5kIENsaW5pY2FsIEV4Y2VsbGVu
Y2UgKE5JQ0UpLDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRs
ZT5NZXRhc3RhdGljIHNwaW5hbCBjb3JkIGNvbXByZXNzaW9uOiBkaWFnbm9zaXMgYW5kIG1hbmFn
ZW1lbnQgb2YgcGF0aWVudHMgYXQgcmlzayBvZiBvciB3aXRoIG1ldGFzdGF0aWMgc3BpbmFsIGNv
cmQgY29tcHJlc3Npb248L3RpdGxlPjwvdGl0bGVzPjxkYXRlcz48eWVhcj4yMDA4PC95ZWFyPjwv
ZGF0ZXM+PHB1Ymxpc2hlcj5OYXRpb25hbCBDb2xsYWJvcmF0aW5nIENlbnRyZSBmb3IgY2FuY2Vy
PC9wdWJsaXNoZXI+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmljZS5vcmcu
dWsvbmljZW1lZGlhL2xpdmUvMTIwODUvNDI2NjgvNDI2NjgucGRmPC91cmw+PC9yZWxhdGVkLXVy
bHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkxvYmxhdzwvQXV0aG9yPjxZ
ZWFyPjIwMDU8L1llYXI+PFJlY051bT40NDk8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ0
OTwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlw
dzlzZWFlZTBkZDd4dHo1bXB3OTB4MnQycmFwZSI+NDQ5PC9rZXk+PC9mb3JlaWduLWtleXM+PHJl
Zi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+
PGF1dGhvcnM+PGF1dGhvcj5Mb2JsYXcsIEQuIEFuZHJldzwvYXV0aG9yPjxhdXRob3I+UGVycnks
IEphbWVzPC9hdXRob3I+PGF1dGhvcj5DaGFtYmVycywgQWxleGFuZHJhPC9hdXRob3I+PGF1dGhv
cj5MYXBlcnJpZXJlLCBOb3JtYW5kIEouPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz
Pjx0aXRsZXM+PHRpdGxlPlN5c3RlbWF0aWMgUmV2aWV3IG9mIHRoZSBEaWFnbm9zaXMgYW5kIE1h
bmFnZW1lbnQgb2YgTWFsaWduYW50IEV4dHJhZHVyYWwgU3BpbmFsIENvcmQgQ29tcHJlc3Npb246
IFRoZSBDYW5jZXIgQ2FyZSBPbnRhcmlvIFByYWN0aWNlIEd1aWRlbGluZXMgSW5pdGlhdGl2ZSBO
ZXVyby1PbmNvbG9neSBEaXNlYXNlIFNpdGUgR3JvdXA8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+
Sm91cm5hbCBvZiBDbGluaWNhbCBPbmNvbG9neTwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxw
ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkpvdXJuYWwgb2YgQ2xpbmljYWwgT25jb2xvZ3k8L2Z1bGwt
dGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz4yMDI4LTIwMzc8L3BhZ2VzPjx2b2x1bWU+MjM8L3Zv
bHVtZT48bnVtYmVyPjk8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAwNTwveWVhcj48L2RhdGVzPjx1
cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vamNvLmFzY29wdWJzLm9yZy9jb250ZW50LzIz
LzkvMjAyOC5hYnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1y
ZXNvdXJjZS1udW0+MTAuMTIwMC9qY28uMjAwNS4wMC4wNjc8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut
bnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+
ADDIN EN.CITE.DATA 12, 22, 23Back pain: Back pain is the most common presenting symptom of people with MSCC, occurring in up to 95% of sufferers.Reduced power: Up to 85% of people with MSCC also have reduced power in their limbs.Loss of sensation: 65% of those with MSCC suffer with loss of sensation.These symptoms can have a devastating effect on the quality of life (QoL) of the person with cancer and their carers. ADDIN EN.CITE <EndNote><Cite><Author>Loblaw</Author><Year>2005</Year><RecNum>449</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Loblaw, D. Andrew</author><author>Perry, James</author><author>Chambers, Alexandra</author><author>Laperriere, Normand J.</author></authors></contributors><titles><title>Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>2028-2037</pages><volume>23</volume><number>9</number><dates><year>2005</year></dates><urls><related-urls><url> People who do experience paralysis due to MSCC also have a shortened life expectancy. ADDIN EN.CITE <EndNote><Cite><Author>Loblaw</Author><Year>2005</Year><RecNum>449</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Loblaw, D. Andrew</author><author>Perry, James</author><author>Chambers, Alexandra</author><author>Laperriere, Normand J.</author></authors></contributors><titles><title>Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>2028-2037</pages><volume>23</volume><number>9</number><dates><year>2005</year></dates><urls><related-urls><url> MSCC can result in irreversible neurological damage. ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22, 23</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Loblaw, D. Andrew</author><author>Perry, James</author><author>Chambers, Alexandra</author><author>Laperriere, Normand J.</author></authors></contributors><titles><title>Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>2028-2037</pages><volume>23</volume><number>9</number><dates><year>2005</year></dates><urls><related-urls><url>, 23 Early recognition and treatment of MSCC can significantly alleviate associated morbidity and improve overall QoL. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12, 22</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url>, 22 A history of any of the above symptoms in a person with cancer warrants urgent investigation.Although the majority of people presenting with MSCC do have a previous history of cancer, for some people, MSCC is the presenting complaint that leads to a cancer diagnosis. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> In people not previously known to have cancer, histology may be sought to confirm the primary diagnosis. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Learning activityCompletedActivity Discuss the implications of compression in different areas of the spine:Cervical spineThoracic spineLumbar spineSacral spineAssessment and monitoringNurses have an important role to play in the education of those at risk of MSCC as it is vitally important that these individuals be made aware of the signs and symptoms of the disease, and when they should seek medical advice. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> As mentioned above, failure to quickly diagnose MSCC is associated with significant morbidity and compromised QoL.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYWxqaTwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYWxqaTwvQXV0aG9yPjxZZWFyPjIwMDg8L1llYXI+PFJl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ADDIN EN.CITE.DATA 12, 23The key investigation for the diagnosis of MSCC is magnetic resonance imaging (MRI) of the spine. ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> This may indicate existing or impending compression of the spinal cord. ADDIN EN.CITE <EndNote><Cite><Author>eviQ</Author><Year>2010</Year><RecNum>448</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>448</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">448</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>eviQ,</author></authors></contributors><titles><title>Radiation oncology, palliation, spinal cord compression (SCC)</title></titles><number>02.06.2011</number><dates><year>2010</year></dates><publisher>Cancer Institute New South Wales</publisher><urls><related-urls><url> In addition to the physical effects of a diagnosis of MSCC, individuals can experience disruptions to their social and psychological health. ADDIN EN.CITE <EndNote><Cite><Author>Pigott</Author><Year>2009</Year><RecNum>460</RecNum><DisplayText><style face="superscript">25, 26</style></DisplayText><record><rec-number>460</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pigott, Cathie</author><author>Pollard, Annabel</author><author>Thomson, Kathryn</author><author>Aranda, Sanchia</author></authors></contributors><titles><title>Unmet needs in cancer patients: development of a supportive needs screening tool (SNST)</title><secondary-title>Supportive Care in Cancer</secondary-title></titles><periodical><full-title>Supportive Care in Cancer</full-title></periodical><pages>33-45</pages><volume>17</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2009</year></dates><publisher>Springer Berlin / Heidelberg</publisher><isbn>0941-4355</isbn><urls><related-urls><url> Breast Cancer Centre</Author><Year>2003</Year><RecNum>65</RecNum><record><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">65</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author>National Breast Cancer Centre,</author><author>National Cancer Control Initiative,</author></authors></contributors><titles><title>Clinical practice guidelines for the psychosocial care of adults with cancer</title></titles><dates><year>2003</year></dates><pub-location>Camperdown, NSW</pub-location><publisher>National Breast Cancer Centre</publisher><urls><related-urls><url>, 26 They can also experience practical needs related to issues like finances and transport. ADDIN EN.CITE <EndNote><Cite><Author>National Breast Cancer Centre</Author><Year>2003</Year><RecNum>65</RecNum><DisplayText><style face="superscript">26</style></DisplayText><record><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">65</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author>National Breast Cancer Centre,</author><author>National Cancer Control Initiative,</author></authors></contributors><titles><title>Clinical practice guidelines for the psychosocial care of adults with cancer</title></titles><dates><year>2003</year></dates><pub-location>Camperdown, NSW</pub-location><publisher>National Breast Cancer Centre</publisher><urls><related-urls><url> Learning activityCompletedActivity Outline the evidence-based education strategies you would use to educate a person with cancer on their risk of developing MSCC. Describe the signs and symptoms of MSCC you would tell them to self- monitor for. Recommended intervention strategiesManagementOnce a diagnosis of MSCC has been made, treatment goals include: ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Clinical Excellence (NICE)</Author><Year>2008</Year><RecNum>446</RecNum><DisplayText><style face="superscript">22</style></DisplayText><record><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">446</key></foreign-keys><ref-type name="Government Document">46</ref-type><contributors><authors><author>National Institute for Health and Clinical Excellence (NICE),</author></authors></contributors><titles><title>Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression</title></titles><dates><year>2008</year></dates><publisher>National Collaborating Centre for cancer</publisher><urls><related-urls><url> pain reliefrestoration of neurological status if possibleprevention of further damage through stabilisation of the spine.Treatment of MSCC should take into consideration the person’s pre-treatment health status, including their ability to ambulate and comorbidities. ADDIN EN.CITE <EndNote><Cite><Author>Loblaw</Author><Year>2005</Year><RecNum>449</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Loblaw, D. Andrew</author><author>Perry, James</author><author>Chambers, Alexandra</author><author>Laperriere, Normand J.</author></authors></contributors><titles><title>Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group</title><secondary-title>Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Journal of Clinical Oncology</full-title></periodical><pages>2028-2037</pages><volume>23</volume><number>9</number><dates><year>2005</year></dates><urls><related-urls><url> Palliative radiotherapy remains the cornerstone of treatment for most people with MSCC. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Urgent surgical opinion should also be sought for the person with actual or impending MSCC, as evidence has suggested that outcomes are improved with decompressive surgery prior to radiotherapy. People with MSCC are also often treated with corticosteroids, although there is currently limited evidence to support this practice. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> than 50% of individuals with MSCC go on to develop urinary retention and faecal incontinence. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Incontinence can have a major impact on QoL. Faecal incontinence is also a leading cause of admittance to a residential aged care facility. ADDIN EN.CITE <EndNote><Cite><Author>Continence Foundation of Australia</Author><Year>2010</Year><RecNum>470</RecNum><DisplayText><style face="superscript">27</style></DisplayText><record><rec-number>470</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">470</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Continence Foundation of Australia,</author></authors></contributors><titles><title>Continence Foundation of Australia home page</title></titles><number>07.07.2011</number><dates><year>2010</year></dates><urls><related-urls><url> Learning activitiesCompletedActivities Discuss the nursing implications of people receiving the following treatments for MSCC: corticosteroidsradiation to the spinal corddecompressive surgeryDiscuss the evidence-based supportive care you could offer a person with MSCC who is suffering with bowel and bladder dysfunction.Superior vena cava syndromeAetiology and contributing factorsSuperior vena cava syndrome (SCVS) is a complication that can arise in people with cancer, especially those with lung cancer or lymphoma. ADDIN EN.CITE <EndNote><Cite><Author>Wan</Author><Year>2009</Year><RecNum>451</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wan, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Emergency medicine clinics of North America</secondary-title></titles><periodical><full-title>Emergency medicine clinics of North America</full-title></periodical><pages>243-255</pages><volume>27</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>28 Approximately two to four percent of all people with lung cancer will go on to develop SVCS at some time. ADDIN EN.CITE <EndNote><Cite><Author>Wan</Author><Year>2009</Year><RecNum>451</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wan, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Emergency medicine clinics of North America</secondary-title></titles><periodical><full-title>Emergency medicine clinics of North America</full-title></periodical><pages>243-255</pages><volume>27</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>28 The superior vena cava (SVC) is responsible for the venous drainage of the head, neck, arms, and upper thorax. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> The SVC has thin walls, and is vulnerable to external compression by tumours arising in the lung or mediastinal area. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Tumour invasion, thrombosis, or interference with the venous return can also cause obstruction of the SVC, leading to SVCS. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> This syndrome is defined by the constellation of symptoms that result from the obstruction of the SCV. ADDIN EN.CITE <EndNote><Cite><Author>Wilson</Author><Year>2007</Year><RecNum>452</RecNum><DisplayText><style face="superscript">16, 30</style></DisplayText><record><rec-number>452</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">452</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wilson, Lynn D. </author><author>Detterbeck, Frank C. </author><author>Yahalom, Joachim </author></authors></contributors><titles><title>Superior Vena Cava Syndrome with Malignant Causes </title><secondary-title>The New England Journal of Medicine</secondary-title></titles><periodical><full-title>The New England Journal of Medicine</full-title></periodical><pages>1862-9</pages><volume>356</volume><number>18</number><dates><year>2007</year></dates><urls><related-urls><url> </Year><RecNum>439</RecNum><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url>, 30Signs and symptoms commonly associated with SVCS include: ADDIN EN.CITE <EndNote><Cite><Author>Wan</Author><Year>2009</Year><RecNum>451</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wan, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Emergency medicine clinics of North America</secondary-title></titles><periodical><full-title>Emergency medicine clinics of North America</full-title></periodical><pages>243-255</pages><volume>27</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>28facial or neck swelling (in 82% of presentations)arm swelling (68%)dyspnoea (66%)cough (50%)dilated chest veins (38%).Swelling is typically described as being worse in the morning, and symptoms of SVCS are generally exacerbated by lying down, bending forward, coughing, or sneezing. All of these actions increase venous pressure. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> clinical presentation of SVCS may be acute or subacute. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> Subacute SVCS may present with minimal or no symptoms and is not considered an oncological emergency. However, 75% of people who present with SVCS have had the symptoms and signs of SVCS for longer than one week before seeking medical advice. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> SVCS can be life threatening if there is evidence of respiratory or neurologic compromise due to the obstruction. ADDIN EN.CITE <EndNote><Cite><Author>Wan</Author><Year>2009</Year><RecNum>451</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wan, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Emergency medicine clinics of North America</secondary-title></titles><periodical><full-title>Emergency medicine clinics of North America</full-title></periodical><pages>243-255</pages><volume>27</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>28 The severity of SVCS depends on the obstruction’s location and how rapid its onset was. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> If the obstruction is above the entry of the azygos vein, the venous system can more readily distend to accommodate the movement of the obstructed blood with less venous pressure then developing . ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> In most cases, because symptoms develop over the course of several weeks, this allows the body to develop collateral circulations to deal with the obstruction. ADDIN EN.CITE <EndNote><Cite><Author>Wan</Author><Year>2009</Year><RecNum>451</RecNum><DisplayText><style face="superscript">28</style></DisplayText><record><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wan, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Emergency medicine clinics of North America</secondary-title></titles><periodical><full-title>Emergency medicine clinics of North America</full-title></periodical><pages>243-255</pages><volume>27</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>28Resource linkReview Medlibes online medical library ADDIN EN.CITE <EndNote><Cite><Author>Medlibes Online Medical Library</Author><Year>2010</Year><RecNum>456</RecNum><DisplayText><style face="superscript">31</style></DisplayText><record><rec-number>456</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">456</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Medlibes Online Medical Library,</author></authors></contributors><titles><title>Superior vena cava syndrome</title></titles><number>03.06.2011</number><dates><year>2010</year></dates><urls><related-urls><url> to see a picture of a person suffering with distension of their veins secondary to SVCO. This may be a presenting symptom of this syndrome.Learning activityCompletedActivity Review the pathophysiology behind the development of collateral circulation in response to SVC obstruction, and discuss the importance of the obstruction location especially in relation to the azygos vein.Assessment and monitoringPeople at risk of developing SVCS must receive education to reinforce the importance of monitoring for the signs and symptoms of the syndrome, and what action needs to be taken in the event of these signs or symptoms developing. Early symptoms of SVCS may be subtle and easily ignored, making effective education of those at risk a priority for cancer nurses. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> of SVCS by radiological study is not always necessary, but may be helpful. Routine studies include x-ray, CT scan, and MRI. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> Histology of the underlying malignancy should also be confirmed, and is typically done via a sputum sample or fine needle aspiration. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> assessment of SCVS should focus on the patency of the airway and the maintenance of cardiac output. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> Frequent assessment of the respiratory, cardiac and neurologic systems is required and may include regular arterial blood gas and coagulation studies. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> Like all people with cancer, those experiencing SVCS may have unmet supportive care needs. Learning activityCompletedActivity Describe the elements of a clinical assessment to identify early signs of SVCS.Recommended intervention strategiesManagementTreatment for SVCS should be individualised, and depends on the underlying aetiology of the obstructive process. ADDIN EN.CITE <EndNote><Cite><Author>Wudel</Author><Year>2001</Year><RecNum>450</RecNum><DisplayText><style face="superscript">29</style></DisplayText><record><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wudel, L.</author><author>Nesbitt, Jonathan</author></authors></contributors><titles><title>Superior vena cava syndrome</title><secondary-title>Current Treatment Options in Oncology</secondary-title></titles><periodical><full-title>Current Treatment Options in Oncology</full-title></periodical><pages>77-91</pages><volume>2</volume><number>1</number><keywords><keyword>Medicine</keyword></keywords><dates><year>2001</year></dates><publisher>Springer Boston</publisher><isbn>1527-2729</isbn><urls><related-urls><url> Ensuring the person’s comfort and safety should be the goal of initial nursing care of SVCS. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> For the person with SVCS, this may be achieved by:PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2dhbjwvQXV0aG9yPjxZZWFyPjE5OTggPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2dhbjwvQXV0aG9yPjxZZWFyPjE5OTggPC9ZZWFyPjxS
ZWNOdW0+NDM5PC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+
MTIsIDE2PC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+NDM5PC9yZWMt
bnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMnIweHMwOXB3OXNlYWVl
MGRkN3h0ejVtcHc5MHgydDJyYXBlIj40Mzk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUg
bmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9y
cz48YXV0aG9yPkhvZ2FuLCBEZW5pc2UgSy48L2F1dGhvcj48YXV0aG9yPlJvc2VudGhhbCwgTGF1
cmllIEQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPk9u
Y29sb2dpYyBlbWVyZ2VuY2llcyBpbiB0aGUgcGF0aWVudCB3aXRoIGx5bXBob21hPC90aXRsZT48
c2Vjb25kYXJ5LXRpdGxlPlNlbWluYXJzIGluIE9uY29sb2d5IE51cnNpbmc8L3NlY29uZGFyeS10
aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TZW1pbmFycyBpbiBPbmNvbG9n
eSBOdXJzaW5nPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzEyLTMyMDwvcGFnZXM+
PHZvbHVtZT4xNDwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxkYXRlcz48eWVhcj4xOTk4IDwv
eWVhcj48L2RhdGVzPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3LnNjaWVuY2Vk
aXJlY3QuY29tLmV6cDAxLmxpYnJhcnkucXV0LmVkdS5hdS9zY2llbmNlP19vYj1NSW1nJmFtcDtf
aW1hZ2VrZXk9Qjc1S0otNEdEQlhHOS05LTEmYW1wO19jZGk9MTMxODAmYW1wO191c2VyPTYyOTIx
JmFtcDtfcGlpPVMwNzQ5MjA4MTk4ODAwMDkwJmFtcDtfb3JpZ2luPXNlYXJjaCZhbXA7X3pvbmU9
cnNsdF9saXN0X2l0ZW0mYW1wO19jb3ZlckRhdGU9MTElMkYzMCUyRjE5OTgmYW1wO19zaz05OTk4
NTk5OTUmYW1wO3djaHA9ZEdMYlZ6Yi16U2tXQSZhbXA7bWQ1PTA4NjkyODNjYThmNWE0NTczZmQ0
MzJlNjYzMDhmZTZiJmFtcDtpZT0vc2RhcnRpY2xlLnBkZjwvdXJsPjwvcmVsYXRlZC11cmxzPjwv
dXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5XYWxqaTwvQXV0aG9yPjxZZWFyPjIw
MDg8L1llYXI+PFJlY051bT4zNTI8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjM1MjwvcmVj
LW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjJyMHhzMDlwdzlzZWFl
ZTBkZDd4dHo1bXB3OTB4MnQycmFwZSI+MzUyPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBl
IG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhv
cnM+PGF1dGhvcj5XYWxqaSwgTjwvYXV0aG9yPjxhdXRob3I+Q2hhbiwgQSBLPC9hdXRob3I+PGF1
dGhvcj5QZWFrZSwgRCBSPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+
PHRpdGxlPkNvbW1vbiBhY3V0ZSBvbmNvbG9naWNhbCBlbWVyZ2VuY2llczogZGlhZ25vc2lzLCBp
bnZlc3RpZ2F0aW9uIGFuZCBtYW5hZ2VtZW50PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlBvc3Rn
cmFkdWF0ZSBNZWRpY2FsIEpvdXJuYWw8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9k
aWNhbD48ZnVsbC10aXRsZT5Qb3N0Z3JhZHVhdGUgTWVkaWNhbCBKb3VybmFsPC9mdWxsLXRpdGxl
PjwvcGVyaW9kaWNhbD48cGFnZXM+NDE4LTQyNzwvcGFnZXM+PHZvbHVtZT44NDwvdm9sdW1lPjxu
dW1iZXI+OTk0PC9udW1iZXI+PGRhdGVzPjx5ZWFyPjIwMDg8L3llYXI+PC9kYXRlcz48dXJscz48
cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3Btai5ibWouY29tL2NvbnRlbnQvODQvOTk0LzQxOC5h
YnN0cmFjdDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u
dW0+MTAuMTEzNi9wZ21qLjIwMDcuMDY3MDMzPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3Jl
Y29yZD48L0NpdGU+PC9FbmROb3RlPn==
ADDIN EN.CITE.DATA 12, 16providing a calm, quiet environmentlimiting physical activitypositioning the person so that they are sitting upadministration of corticosteroidsproviding oxygen therapy to relieve dyspnoea.The symptoms of SVCS can be distressing for the person and their carers. The nurse is in a position to greatly relieve these fears and concerns through the provision of supportive care. ADDIN EN.CITE <EndNote><Cite><Author>Hogan</Author><Year>1998 </Year><RecNum>439</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hogan, Denise K.</author><author>Rosenthal, Laurie D.</author></authors></contributors><titles><title>Oncologic emergencies in the patient with lymphoma</title><secondary-title>Seminars in Oncology Nursing</secondary-title></titles><periodical><full-title>Seminars in Oncology Nursing</full-title></periodical><pages>312-320</pages><volume>14</volume><number>4</number><dates><year>1998 </year></dates><urls><related-urls><url> the majority of people, SVCS is not immediately life threatening and can be treated conservatively. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Radiotherapy has historically been the treatment of choice for SVCS caused by malignancy, with treatment providing complete symptomatic relief to the majority of sufferers. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> Antineoplastic agents may also reduce tumour bulk and so ease SVCS. ADDIN EN.CITE <EndNote><Cite><Author>Walji</Author><Year>2008</Year><RecNum>352</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Walji, N</author><author>Chan, A K</author><author>Peake, D R</author></authors></contributors><titles><title>Common acute oncological emergencies: diagnosis, investigation and management</title><secondary-title>Postgraduate Medical Journal</secondary-title></titles><periodical><full-title>Postgraduate Medical Journal</full-title></periodical><pages>418-427</pages><volume>84</volume><number>994</number><dates><year>2008</year></dates><urls><related-urls><url> activitiesCompletedActivitiesOutline the rationale behind the administration of corticosteroids to people with SVCS.Discuss the surgical treatment options for the management of SVCS, and the nursing implications of this treatment.Disseminated Intravascular CoagulationAetiology and contributing factorsDisseminated intravascular coagulation (DIC) is characterised by simultaneously occurring widespread microvascular thrombosis, and profuse bleeding from multiple sites. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> is not a disease in, and of, itself, but is always secondary to an underlying disorder. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> Common clinical conditions that may be associated with the occurrence of DIC include severe infection, trauma, and malignancy.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZXZpPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVj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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MZXZpPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVj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ADDIN EN.CITE.DATA 32, 33DIC occurs as a result of dysfunctions within the body’s coagulation system. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34, 35</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url>, 35 DIC may be a complication of both solid tumours and haematological malignancies. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> There is evidence that some solid tumours may express a specific substance that may initiate the activation of DIC. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> In addition, acute promyelocytic leukaemia may trigger a specific form of DIC. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> in DIC is caused by the consumption of available pro-coagulants (such as platelets, prothrombin, and fibrinogen) in response to the ongoing, widespread activation of the coagulation system. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> This process can lead to the deposition of fibrin in the microcirculation, causing blood clots (thromboses). ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36 Clots are unable to be generated where they are needed, in order to stop haemorrhage due to a lack of effective pro-coagulants. ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36In practice, DIC can sometimes be confused with thrombocytopaenic purpure (TTP), as both conditions can cause acute illness associated with multiorgan failure, disseminated thrombosis, and haemorrhagic manifestations. ADDIN EN.CITE <EndNote><Cite><Author>Zhaoyue Wang</Author><Year>2011</Year><RecNum>1185</RecNum><DisplayText><style face="superscript">37</style></DisplayText><record><rec-number>1185</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Zhaoyue Wang,</author><author>Ziqiang Yu,</author><author>Jian Su,</author><author>Lijuan Cao,</author><author>Xiaojuan Zhao,</author><author>Changgeng Ruan,</author></authors></contributors><titles><title>Sepsis-Induced Disseminated Intravascular Coagulation With Features of Thrombotic Thrombocytopenic Purpura: A Fatal Fulminant Syndrome</title><secondary-title>Clinical and Applied Thrombosis/Hemostasis</secondary-title></titles><periodical><full-title>Clinical and Applied Thrombosis/Hemostasis</full-title></periodical><pages>251-253</pages><volume>17</volume><number>3</number><dates><year>2011</year></dates><urls><related-urls><url> However, DIC can be differentiated from TTP pathologically in that it causes consumption of clotting factors and interferes with fibrinolysis. ADDIN EN.CITE <EndNote><Cite><Author>Zhaoyue Wang</Author><Year>2011</Year><RecNum>1185</RecNum><DisplayText><style face="superscript">37</style></DisplayText><record><rec-number>1185</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Zhaoyue Wang,</author><author>Ziqiang Yu,</author><author>Jian Su,</author><author>Lijuan Cao,</author><author>Xiaojuan Zhao,</author><author>Changgeng Ruan,</author></authors></contributors><titles><title>Sepsis-Induced Disseminated Intravascular Coagulation With Features of Thrombotic Thrombocytopenic Purpura: A Fatal Fulminant Syndrome</title><secondary-title>Clinical and Applied Thrombosis/Hemostasis</secondary-title></titles><periodical><full-title>Clinical and Applied Thrombosis/Hemostasis</full-title></periodical><pages>251-253</pages><volume>17</volume><number>3</number><dates><year>2011</year></dates><urls><related-urls><url> often causes multiorgan dysfunction, either by haemorrhages occurring in these organs or by clots disrupting the circulation of blood to them. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> Multiorgan dysfunction may lead to death. Mortality from DIC depends on the underlying disease causing the syndrome, and the severity of coagulation dysfunction experienced. ADDIN EN.CITE <EndNote><Cite><Author>Becker</Author><Year>2011</Year><RecNum>1192</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1192</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1192</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Becker, Joseph U.</author><author>Kumar, Avishek</author><author>Salim Shaaban, Hamid</author><author>Wira, Charles R.</author></authors></contributors><titles><title>Disseminated intravascular coagulation in emergency medicine</title></titles><number>22.02.2012</number><dates><year>2011</year></dates><publisher>Medscape Reference</publisher><urls><related-urls><url> Overall, the mortality rate of DIC is between 10 and 50%. ADDIN EN.CITE <EndNote><Cite><Author>Becker</Author><Year>2011</Year><RecNum>1192</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1192</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1192</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Becker, Joseph U.</author><author>Kumar, Avishek</author><author>Salim Shaaban, Hamid</author><author>Wira, Charles R.</author></authors></contributors><titles><title>Disseminated intravascular coagulation in emergency medicine</title></titles><number>22.02.2012</number><dates><year>2011</year></dates><publisher>Medscape Reference</publisher><urls><related-urls><url> DIC associated with sepsis has a much higher mortality rate then DIC associated with trauma. ADDIN EN.CITE <EndNote><Cite><Author>Becker</Author><Year>2011</Year><RecNum>1192</RecNum><DisplayText><style face="superscript">38</style></DisplayText><record><rec-number>1192</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1192</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Becker, Joseph U.</author><author>Kumar, Avishek</author><author>Salim Shaaban, Hamid</author><author>Wira, Charles R.</author></authors></contributors><titles><title>Disseminated intravascular coagulation in emergency medicine</title></titles><number>22.02.2012</number><dates><year>2011</year></dates><publisher>Medscape Reference</publisher><urls><related-urls><url> activityCompletedActivityExplain why people with acute promyelocytic leukaemia are at increased risk of developing DIC.Assessment and monitoringClinically, individuals with DIC may present with symptoms of blood clots, excessive bleeding, or both. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> Clots associated with DIC can lead to tissue necrosis, ischaemia, and organ failure. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1181</RecNum><DisplayText><style face="superscript">32, 36</style></DisplayText><record><rec-number>1181</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, Marcel</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title><secondary-title>Journal of Coagulation Disorders</secondary-title></titles><periodical><full-title>Journal of Coagulation Disorders</full-title></periodical><pages>55-63</pages><volume>3</volume><number>1</number><dates><year>2011</year></dates><urls><related-urls><url> app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>32, 36 Conversely, the individual affected by DIC may present with signs and symptoms of excessive bleeding, including epistaxis, bleeding from wounds, petechiae and ecchymoses. ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36 Because of the nature of DIC, those affected may present with symptoms of both bleeding and excessive clotting. Below are two images of a person with DIC secondary to infection. ADDIN EN.CITE <EndNote><Cite><Author>Lipsker</Author><Year>2008</Year><RecNum>1186</RecNum><DisplayText><style face="superscript">39</style></DisplayText><record><rec-number>1186</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lipsker, Dan</author><author>Kara, Fady</author></authors></contributors><titles><title>Retiform Purpura</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>e1</pages><volume>358</volume><number>2</number><dates><year>2008</year></dates><urls><related-urls><url> These images come from the New England Journal of Medicine Images in Clinical Medicine series, and are used with permission.Image A shows a purpuric rash. Image B shows the occurrence of retiform purpura on the sole of a foot. Retiform purpura appears in a net-like pattern and is an indication of thrombosed veins. ADDIN EN.CITE <EndNote><Cite><Author>Lipsker</Author><Year>2008</Year><RecNum>1186</RecNum><DisplayText><style face="superscript">39</style></DisplayText><record><rec-number>1186</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lipsker, Dan</author><author>Kara, Fady</author></authors></contributors><titles><title>Retiform Purpura</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><pages>e1</pages><volume>358</volume><number>2</number><dates><year>2008</year></dates><urls><related-urls><url> Lipsker D, Kara F. Retiform Purpura. New England Journal of Medicine. 2008;358(2):e1.Used with permissionThe diagnosis of DIC needs to be based on both clinical and pathological information. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url> There is no single test that can rule out or confirm DIC. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url> DIC can progress very quickly and so any assessment done needs to keep pace with the critical nature of this condition. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url>, DIC causes abnormalities in prothrombin time (PT) and partial thromboplastin time (PTT), thrombocytopaenia, and decreased fibrinogen levels. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> People with DIC also generally show increased levels of fibrin degradation products (FDPs). ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> The whole spectrum of the individual’s pathology results must be considered in diagnosing DIC, as each of these results on their own is not necessarily indicative of the syndrome. For instance, fibrinogen levels can be normal in as many as 57% of people with DIC. Sequential measurements might be more useful when establishing a diagnosis. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url> Because the coagulation system is dysfunctional in someone with DIC, the risk of thrombosis is not a function of platelet count, and thrombocytopaenia does not necessarily protect the person with DIC from thrombosis. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> International Society for Thrombosis and Haemostasis (ISTH) provides a scoring system ADDIN EN.CITE <EndNote><Cite><Author>Toh</Author><Year>2007</Year><RecNum>1188</RecNum><DisplayText><style face="superscript">41</style></DisplayText><record><rec-number>1188</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Toh, C. H.</author><author>Hoots, W. K.</author><author>Ssc On Disseminated Intravascular Coagulation Of The, Isth</author></authors></contributors><titles><title>The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview1</title><secondary-title>Journal of Thrombosis and Haemostasis</secondary-title></titles><periodical><full-title>Journal of Thrombosis and Haemostasis</full-title></periodical><pages>604-606</pages><volume>5</volume><number>3</number><dates><year>2007</year></dates><publisher>Blackwell Publishing Ltd</publisher><isbn>1538-7836</isbn><urls><related-urls><url> for the objective pathological measurement of DIC. This system differentiates between DIC that is non-overt (where the body is able to compensate well with any derangement in clotting factors) and overt DIC (in which the body is haemostatically compromised). ADDIN EN.CITE <EndNote><Cite><Author>Taylor Jr</Author><Year>2001</Year><RecNum>1189</RecNum><DisplayText><style face="superscript">42</style></DisplayText><record><rec-number>1189</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1189</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Taylor Jr, Fletcher B.</author><author>Toh, Cheng-Hock</author><author>Hoots, W. Keith</author><author>Wada, Hideo</author><author>Levi, Marcel</author></authors></contributors><titles><title>Scientific and Standardizat ion Committee Communications: Towards a Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation on behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis</title></titles><number>22.02.2012</number><dates><year>2001</year></dates><urls><related-urls><url> Use of the ISTH system may be problematic, however, when used in incorrect clinical situations or with illnesses that may mimic DIC. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> Clinical assessment of DIC is thus also important in the diagnosis of this syndrome.Learning activityCompletedActivityIdentify the normal ranges and ranges indicative of DIC for the following pathology results:Prothrombin timePartial thromboplastin timePlateletsFibrinogenD-dimer.Recommended intervention strategiesPreventionPrompt nursing assessment and management of those at risk of DIC may lead to better outcomes for affected individuals. ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36 For example, DIC may affect up to 50% of people with sepsis. ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36 Prompt recognition and treatment of sepsis may help prevent the processes that trigger the initiation of DIC. ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36 See febrile neutropaenia and sepsis evidence summary for more information on these conditions.ManagementTreatment of the underlying cause of DIC is crucial to the long term prognosis of the affected person. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LaXRjaGVuczwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LaXRjaGVuczwvQXV0aG9yPjxZZWFyPjIwMDk8L1llYXI+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ADDIN EN.CITE.DATA 32, 34, 40 If the underlying cause is reversible, such as obstetric trauma, then recovery from DIC is likely. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> DIC may even spontaneously resolve when this underlying cause is treated. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url> If the DIC trigger is a chronic or irreversible disease, the resolution of DIC is more difficult and prognosis is much poorer. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> individuals with DIC require aggressive resuscitation to maintain optimal fluid balance, blood pressure, temperature and serum pH. HYPERLINK \l "_ENREF_34" \o "Kitchens, 2009 #1190" ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> Key aspects of supportive treatment for DIC may include transfusion of blood products, anticoagulant therapy, and restoration of normal anticoagulant pathways. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> blood cells, platelets, fresh frozen plasma, and cryoprecipitate have all be used in the treatment of DIC. ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> Use of blood products should not occur in response to pathology results alone, but may be indicated in individuals with active bleeding, those requiring and invasive procedure, or those otherwise at risk for bleeding complications. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url> Resource linkThe Australian Red Cross Blood Service (ARCBS) has an overview of DIC on their website, and include current ARCBS recommendations for use of blood products to manage DIC. ADDIN EN.CITE <EndNote><Cite><Author>Australian Red Cross Blood Service</Author><Year>2010</Year><RecNum>1196</RecNum><DisplayText><style face="superscript">43</style></DisplayText><record><rec-number>1196</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1196</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Australian Red Cross Blood Service,</author></authors></contributors><titles><title>Management of DIC</title></titles><number>23.02.2012</number><dates><year>2010</year></dates><urls><related-urls><url> may be used in cases of DIC where thrombosis is the predominant issue. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2009</Year><RecNum>1184</RecNum><DisplayText><style face="superscript">40</style></DisplayText><record><rec-number>1184</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levi, M.</author><author>Toh, C. H.</author><author>Thachil, J.</author><author>Watson, H. G.</author></authors></contributors><titles><title>Guidelines for the diagnosis and management of disseminated intravascular coagulation</title><secondary-title>British Journal of Haematology</secondary-title></titles><periodical><full-title>British Journal of Haematology</full-title></periodical><pages>24-33</pages><volume>145</volume><number>1</number><keywords><keyword>DISSEMINATED intravascular coagulation</keyword><keyword>HEMOSTASIS</keyword><keyword>CARDIOVASCULAR system -- Diseases</keyword><keyword>CLINICAL medicine</keyword><keyword>BLOOD coagulation disorders</keyword><keyword>anticoagulation</keyword><keyword>blood coagulation</keyword><keyword>coagulation factors</keyword><keyword>thrombosis</keyword></keywords><dates><year>2009</year></dates><publisher>Wiley-Blackwell</publisher><isbn>00071048</isbn><urls><related-urls><url> However, there is a paucity of controlled clinical trials in the use of anticoagulants when managing DIC. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> Therapeutic doses of heparin are indicated in individuals with clinically overt thromboembolism. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> The benefits of using anticoagulants must be weighed against the risk of them contributing to worsening bleeding. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> of anticoagulant pathways may include administration of recombinant human activated protein C or antithrombin concentrate. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> Further study regarding use of these agents is required to demonstrate their safety and efficacy. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> management for those at risk of DIC includes regular assessment for signs or symptoms of the condition and supportive care strategies to manage them, including: ADDIN EN.CITE <EndNote><Cite><Author>Kitchens</Author><Year>2009</Year><RecNum>1190</RecNum><DisplayText><style face="superscript">34</style></DisplayText><record><rec-number>1190</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kitchens, Craig S.</author></authors></contributors><titles><title>Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC)</title><secondary-title>ASH Education Program Book</secondary-title></titles><periodical><full-title>ASH Education Program Book</full-title></periodical><pages>240-246</pages><number>1</number><dates><year>2009</year></dates><urls><related-urls><url> from IV sites, mucous membranes or woundsoccurrence or worsening of rashes.Individuals with known DIC are also monitored closely, with collection of serial coagulation panels, to evaluate the effectiveness of interventions and inform any further therapy. ADDIN EN.CITE <EndNote><Cite><Author>Dressler</Author><Year>2009</Year><RecNum>1191</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>1191</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dressler, Diane K.</author></authors></contributors><titles><title>Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation</title><secondary-title>AACN Advanced Critical Care</secondary-title></titles><periodical><full-title>AACN Advanced Critical Care</full-title></periodical><pages>166-176</pages><volume>20</volume><number>2</number><dates><year>2009</year></dates><urls></urls></record></Cite></EndNote>36Resource linkMedscape reference article: Disseminated intravascular coagulation. ADDIN EN.CITE <EndNote><Cite><Author>Levi</Author><Year>2011</Year><RecNum>1194</RecNum><DisplayText><style face="superscript">35</style></DisplayText><record><rec-number>1194</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1194</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Levi, Marcel M.</author><author>Schmaier, Alvin H.</author></authors></contributors><titles><title>Disseminated intravascular coagulation</title></titles><number>23.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> (This is a free resource, but you have to register and login to access).Learning activitiesCompletedActivities Access the ARCBS recommendations for use of blood products to manage DIC ADDIN EN.CITE <EndNote><Cite><Author>Australian Red Cross Blood Service</Author><Year>2010</Year><RecNum>1196</RecNum><DisplayText><style face="superscript">43</style></DisplayText><record><rec-number>1196</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1196</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Australian Red Cross Blood Service,</author></authors></contributors><titles><title>Management of DIC</title></titles><number>23.02.2012</number><dates><year>2010</year></dates><urls><related-urls><url>, and summarise the recommendations for the use of:plateletsred blood cellsfresh frozen plasmacryoprecipitate.Describe the nursing assessment and management of an individual experiencing epistaxis.HypercalcaemiaAetiology and contributing factorsHypercalcaemia is a metabolic abnormality that affects up to 30% of people with cancer.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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ADDIN EN.CITE.DATA 44-46 It more commonly occurs in those with advanced cases of the disease. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 In a healthy person, serum calcium is kept within normal levels by homeostatic mechanisms designed to balance the flow of calcium between bone, kidneys, intestines, and extracellular fluid. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 Calcium is released from food, and from the normal breakdown of bones by osteoclasts.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44 In what is normally a continuous cycle, osteoblasts then utilise calcium when rebuilding new bone.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44 Excess calcium is excreted by the kidneys.Hypercalcaemia occurs when normal homeostatic mechanisms are overwhelmed. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 In hypercalcaemia associated with malignancy, excessive amounts of calcium are released from bones as a result of abnormal bone loss, and the kidneys are unable to ‘keep up’ with the amount of calcium that needs to be excreted. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46There are many factors that may cause bone loss in people with cancer. The major cause is the presence of bone metastases. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> Certain malignancies are more commonly associated with bone loss. These include prostate cancer, breast cancer, and multiple myeloma. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> Bone metastases affect up to 75% of men with advanced prostate cancer, and up to 75% of women with advanced breast cancer. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> Bone lesions are seen in up to 100% of people with multiple myeloma. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> Bone loss in those with cancer may also be related to their age, and to cancer treatments. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> Common treatments for advanced prostate cancer can themselves cause bone loss. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> and monitoringSymptoms of hypercalcaemia may be non-specific and easily confused with those of the underlying cancer or its treatment. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">45, 46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45, 46 Consequently, it is important to consider the possibility of hypercalcaemia in any person with suggestive symptoms. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46The effects of hypercalcaemia are systemic and produce a wide range of symptoms. These include: ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">45, 46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45, 46renal dysfunction (possibly indicated by polyuria and/or polydipsia)effects on the gastrointestinal system (anorexia, nausea, vomiting, constipation)cardiac arrhythmiascentral nervous system (CNS) abnormalities (confusion, seizures, muscle weakness)generalised malaise and fatigue.Individual responses to hypercalcaemia can be variable, but most people affected will display at least some symptoms.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44 If these symptoms are not recognised, the person affected will progressively become more unwell.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44 By recognising symptoms in the early stages, nurses may be able to facilitate improved outcomes for those affected by hypercalcaemia.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44The diagnosis and monitoring of hypercalcaemia is done pathologically, by examining the total serum calcium values and adjusting for albumin concentrations. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 Renal function should also be monitored in those with hypercalcaemia, and ECGs performed to ensure no cardiac abnormalities are occurring. ADDIN EN.CITE <EndNote><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><DisplayText><style face="superscript">45</style></DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45 In some individuals, hypercalcaemia is the presenting symptom of cancer and they require a full work up to diagnose the type of malignancy and the presence of any bone metastases. ADDIN EN.CITE <EndNote><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><DisplayText><style face="superscript">45</style></DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45Recommended intervention strategiesPreventionComprehensive cancer care should include recognition of the importance of the bone health of people affected by cancer. ADDIN EN.CITE <EndNote><Cite><Author>Lipton</Author><Year>2009</Year><RecNum>1</RecNum><DisplayText><style face="superscript">47</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author> Lipton, Allan</author><author>Uzzo, Robert </author><author>Amato, Robert J. </author><author>Ellis, Georgiana K.</author><author>Hakimian, Behrooz </author><author>Roodman, David </author><author>Smith, Matthew R. </author></authors></contributors><titles><title>The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors</title><secondary-title>Journal of the National Comprehensive Cancer Network (JNCCN)</secondary-title></titles><periodical><full-title>Journal of the National Comprehensive Cancer Network (JNCCN)</full-title></periodical><volume>7</volume><number>Supplement 7</number><dates><year>2009</year></dates><urls><related-urls><url> Providing effective education to those at risk of hypercalcaemia will assist in highlighting the symptoms they should self-monitor for, and may help ensure rapid diagnosis and treatment.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44The widespread use of prophylactic bisphosphonates for those with known bone metastases (in order to prevent skeletal events) has probably contributed to a reduction in the incidence rate of hypercalcaemia, though this is impossible to measure. ADDIN EN.CITE <EndNote><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><DisplayText><style face="superscript">45</style></DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45ManagementEffective management of hypercalcaemia may improve symptoms for people affected by cancer, and may even prolong their overall survival. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">45, 46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45, 46 The first step to managing hypercalcaemia is to treat the underlying malignancy. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 In some cases it is also necessary to administer antihypercalcaemic therapy while waiting for antitumour treatments to work, or in those for whom cancer treatment is unavailable or ineffective. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46Antihypercalcaemic treatment may include rehydration. Dehydration – secondary to anorexia or vomiting – may occur as a result of cancer treatments and can worsen hypercalcaemia. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 Hypercalcaemia can also lead to worsening dehydration by impairing urinary concentrating ability, while promoting water excretion. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 Rehydration should therefore be considered in all people with hypercalcaemia. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46Another common antihypercalcaemic treatment is the use of bisphosphonates. Bisphosphonates work to inhibit bone resorption by causing apoptosis of osteoclasts.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5SYWxzdG9uPC9BdXRob3I+PFllYXI+MjAwNTwvWWVhcj48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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5SYWxzdG9uPC9BdXRob3I+PFllYXI+MjAwNTwvWWVhcj48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 EN.CITE.DATA 46, 47 Bisphosphonates are generally the antihypercalcaemic treatment of choice and many different kinds have been used. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46 Other less common treatments for hypercalcaemia include calcitonin, phosphate, and antitumour antibiotics, but these treatments have generally been superseded by the use of bisphosphonates. ADDIN EN.CITE <EndNote><Cite><Author>Ralston</Author><Year>2005</Year><RecNum>4</RecNum><DisplayText><style face="superscript">46</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">4</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Ralston, Stuart H.</author></authors><secondary-authors><author>Jasmin, Claude</author><author>Coleman, Robert E.</author><author>Coia, Lawrence R.</author><author>Capanna, Rodolfo</author><author>Saillant, Gerard</author></secondary-authors></contributors><titles><title>Management of hypercalcaemia</title><secondary-title>Textbook of bone metastases</secondary-title></titles><dates><year>2005</year></dates><publisher>John Wiley and Sons</publisher><urls></urls><electronic-resource-num>10.1002/0470011610</electronic-resource-num></record></Cite></EndNote>46Discontinuing other treatments that may increase serum calcium is also necessary for effective treatment of hypercalcaemia. ADDIN EN.CITE <EndNote><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><DisplayText><style face="superscript">45</style></DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45 This may include stopping any calcium supplementation, thiazide diuretics, or lithium. ADDIN EN.CITE <EndNote><Cite><Author>Basso</Author><Year>2010</Year><RecNum>5</RecNum><DisplayText><style face="superscript">45</style></DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="de2fdtsz3efstmetsz45dxr8a2vsfvvap992">5</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Basso, Umberto</author><author>Roma, Anna</author><author>Brunello, Antonella</author></authors><secondary-authors><author>Lumachi, Franco</author><author>Basso, Stefano M.M.</author></secondary-authors></contributors><titles><title>Hypercalcemia and malignancy</title><secondary-title>Hypercalcemia pathophysiology and treatment</secondary-title></titles><dates><year>2010</year></dates><pub-location>UAE</pub-location><publisher>Bentham Science</publisher><urls></urls></record></Cite></EndNote>45Nurses have an important role to play in supporting the individual affected by hypercalcaemia, and in managing the side effects of this illness.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44 Close observation is often necessary in those suffering with cardiac or CNS dysfunction secondary to hypercalcaemia.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Gb3Vsa2VzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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=
ADDIN EN.CITE.DATA 44 Learning activitiesCompletedActivities Outline the normal ranges and significance of the following blood tests in hypercalcaemia:serum calciumcorrected calciumcreatinine.Develop a care plan for a person with hypercalcaemia. Discuss the rationales for nursing interventions with your mentor/ facilitator.Discuss the core components of an education plan for the person affected by cancer who is at increased risk of developing hypercalcaemia.Managing hazards in the delivery of cancer carePrinciples of radiation safetyRadiation safety principles aim to limit exposure to ionising radiation for radiation therapy personnel, people affected by cancer and the general public. Wherever there is known risk of exposure to ionising radiation, health professionals must be guided by the ALARA (as low as reasonably achievable) principles of radiation safety for time, distance and shielding. ADDIN EN.CITE <EndNote><Cite><Author>Haas</Author><Year>2001</Year><RecNum>659</RecNum><DisplayText><style face="superscript">48, 49</style></DisplayText><record><rec-number>659</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">659</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Haas, M.L.</author><author>Kuehn, E.F.</author></authors><secondary-authors><author>Watkins-Bruner, D.</author><author>Moore-Higgs, G.</author><author>Haas, M.</author></secondary-authors></contributors><titles><title>Teletherapy: External radiation therapy</title><secondary-title>Outcomes in radiation therapy.</secondary-title></titles><pages>55-66</pages><dates><year>2001</year></dates><pub-location>Boston</pub-location><publisher>Jones & Bartlett</publisher><urls></urls></record></Cite><Cite><Author>McQuestion</Author><Year>2007</Year><RecNum>674</RecNum><record><rec-number>674</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">674</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>McQuestion, M.</author></authors><secondary-authors><author>Haas, M.</author><author>Hogle, G.J.</author><author>Moore-Higgs, G.</author><author>Gosselin-Acomb, T.K.</author></secondary-authors></contributors><titles><title>Radiation protection and safety</title><secondary-title>Radiation therapy: a guide to patient care</secondary-title></titles><dates><year>2007</year></dates><pub-location>St Louis</pub-location><publisher>Mosby Elsevier</publisher><urls></urls></record></Cite></EndNote>48, 49 TimeThe less time spent near a radiation source, the less radiation absorbed. This is especially important for personnel such as radiation therapists and physicists preparing radioactive sources, and for nursing staff when caring for individuals who have a radioactive source in a body tissue or cavity. In the case of inpatients, nurses should restrict direct contact to 30 minutes per 8-hour shift. ADDIN EN.CITE <EndNote><Cite><Author>McQuestion</Author><Year>2007</Year><RecNum>674</RecNum><DisplayText><style face="superscript">49</style></DisplayText><record><rec-number>674</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">674</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>McQuestion, M.</author></authors><secondary-authors><author>Haas, M.</author><author>Hogle, G.J.</author><author>Moore-Higgs, G.</author><author>Gosselin-Acomb, T.K.</author></secondary-authors></contributors><titles><title>Radiation protection and safety</title><secondary-title>Radiation therapy: a guide to patient care</secondary-title></titles><dates><year>2007</year></dates><pub-location>St Louis</pub-location><publisher>Mosby Elsevier</publisher><urls></urls></record></Cite></EndNote>49.DistanceThe inverse-square law states that radiation exposure and distance are inversely related. That means that as the distance from the source increases, the intensity of radiation decreases. ADDIN EN.CITE <EndNote><Cite><Author>Dunne-Daly</Author><Year>1997</Year><RecNum>675</RecNum><DisplayText><style face="superscript">50</style></DisplayText><record><rec-number>675</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">675</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Dunne-Daly, C. </author></authors><secondary-authors><author>Dow, K. H.</author><author>Bucholtz, J.H.</author><author>Iwamoto, R. </author><author>Fieler, V. </author><author>Hilderley, L.</author></secondary-authors></contributors><titles><title>Principles of brachytherapy</title><secondary-title>Nursing care in radiation oncology</secondary-title></titles><pages>21-35</pages><dates><year>1997</year></dates><pub-location>Philadelphia</pub-location><publisher>W.B. Saunders</publisher><urls></urls></record></Cite></EndNote>50ShieldingThe appropriate selection of a shielding device is dependent the range of emission of the radioactive source and type of isotype. Standard shielding devices include lead aprons, thyroid shields, and eye shields. Rooms that house x-ray generating equipment are shielded using specified materials. Radioactive sources need to be transported by licensed personnel in lead containers. ADDIN EN.CITE <EndNote><Cite><Author>McQuestion</Author><Year>2007</Year><RecNum>674</RecNum><DisplayText><style face="superscript">49</style></DisplayText><record><rec-number>674</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">674</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>McQuestion, M.</author></authors><secondary-authors><author>Haas, M.</author><author>Hogle, G.J.</author><author>Moore-Higgs, G.</author><author>Gosselin-Acomb, T.K.</author></secondary-authors></contributors><titles><title>Radiation protection and safety</title><secondary-title>Radiation therapy: a guide to patient care</secondary-title></titles><dates><year>2007</year></dates><pub-location>St Louis</pub-location><publisher>Mosby Elsevier</publisher><urls></urls></record></Cite></EndNote>49 Brachytherapy procedures are undertaken in a specialised unit or ward with appropriate facilities, and individuals are generally isolated in a single room. Departments are designed with radiation protection and shielding at the forefront of planning. Radiation therapy workers are required to wear thermoluminescent dosimetry (TLD) badges, monitored by regulatory authorities to measure radiation exposure. Other radiation measurement devices such as Geiger counters are used to monitor areas where radioactive sources are used. Appropriate signage must be in place in the presence of any radioactive substance, and education and information provided to all relevant individuals. ADDIN EN.CITE <EndNote><Cite><Author>Haas</Author><Year>2001</Year><RecNum>659</RecNum><DisplayText><style face="superscript">48, 49</style></DisplayText><record><rec-number>659</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">659</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Haas, M.L.</author><author>Kuehn, E.F.</author></authors><secondary-authors><author>Watkins-Bruner, D.</author><author>Moore-Higgs, G.</author><author>Haas, M.</author></secondary-authors></contributors><titles><title>Teletherapy: External radiation therapy</title><secondary-title>Outcomes in radiation therapy.</secondary-title></titles><pages>55-66</pages><dates><year>2001</year></dates><pub-location>Boston</pub-location><publisher>Jones & Bartlett</publisher><urls></urls></record></Cite><Cite><Author>McQuestion</Author><Year>2007</Year><RecNum>674</RecNum><record><rec-number>674</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">674</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>McQuestion, M.</author></authors><secondary-authors><author>Haas, M.</author><author>Hogle, G.J.</author><author>Moore-Higgs, G.</author><author>Gosselin-Acomb, T.K.</author></secondary-authors></contributors><titles><title>Radiation protection and safety</title><secondary-title>Radiation therapy: a guide to patient care</secondary-title></titles><dates><year>2007</year></dates><pub-location>St Louis</pub-location><publisher>Mosby Elsevier</publisher><urls></urls></record></Cite></EndNote>48, 49Spill managementIn the event of a radiation incident, such as the loss of a source or a spill, appropriate procedures and notifications must be followed. These should be clearly outlined in the clinical environment as part of radiation safety and hospital policy. After ingestion of a radioactive substance, 'spills' generally refer to the loss of body fluid – either urine or vomit – and can be classified as major or minor. A significant amount of fluid loss (vomit or urine) within the first 24 hours would be defined as a major spill. ADDIN EN.CITE <EndNote><Cite><Author>Temple</Author><Year>2007</Year><RecNum>676</RecNum><DisplayText><style face="superscript">51</style></DisplayText><record><rec-number>676</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">676</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Temple, S.V. </author></authors><secondary-authors><author>Haas, M.</author><author>Hogle, G.J.</author><author>Moore-Higgs, G.</author><author>Gosselin-Acomb, T.K.</author></secondary-authors></contributors><titles><title>Radiopharmaceuticals</title><secondary-title>Radiation therapy: a guide to patient care</secondary-title></titles><dates><year>2007</year></dates><pub-location>St Louis</pub-location><publisher>Mosby Elsevier</publisher><urls></urls></record></Cite></EndNote>51Learning activitiesCompletedActivities Summarise how the ALARA principles are implemented in the care of individuals after the following treatments:iodine-131 swallow for thyroid cancerpermanent seed implants in the prostatecaesium-137 insert for cervical cancer using a remote afterloading device.Refer to your local policy and procedures and outline spill management for a radioactive substance. Identify possible risks in your facility for exposure to ionizing radiation.Identify key content for an education program for new cancer care staff to prevent exposure to radiation.Principles for cytotoxic safety Exposure to antineoplastic agents poses a potential health risk to staff who:prepare, handle, or administer the drugscare for individuals following administrationdispose of these drugs or related waste. Many antineoplastic agents, proven to be carcinogenic, mutagenic and teratogenic, are classified as hazardous substances. Direct exposure to antineoplastic agents can occur during administration or handling, and involves inhalation, ingestion or absorption.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Xb3JrY292ZXIgTlNXPC9BdXRob3I+PFllYXI+MjAwODwv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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Xb3JrY292ZXIgTlNXPC9BdXRob3I+PFllYXI+MjAwODwv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=
ADDIN EN.CITE.DATA 52-54Safe levels of occupational exposure to hazardous agents and a reliable method of monitoring exposure have proven difficult to determine. ADDIN EN.CITE <EndNote><Cite><Author>Polovich</Author><Year>2009</Year><RecNum>742</RecNum><DisplayText><style face="superscript">55</style></DisplayText><record><rec-number>742</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">742</key></foreign-keys><ref-type name="Edited Book">28</ref-type><contributors><authors><author>Polovich, M.</author><author>Whitford, J.</author><author>Olsen, N.</author></authors></contributors><titles><title>Chemotherapy and biotherapy guidelines and recommendations for practice</title></titles><edition>3rd</edition><dates><year>2009</year></dates><pub-location>Philadelphia</pub-location><publisher>Oncology Nursing Society</publisher><urls></urls></record></Cite></EndNote>55 The health risk of any procedure involving antineoplastic agents stems from the inherent toxicity of the drug and the extent to which individuals are exposed. Health professionals working with antineoplastic agents are directed by guidelines, policies, and procedures to ensure maintenance of standards of care and to reduce occupational exposure. ADDIN EN.CITE <EndNote><Cite><Author>Carrington</Author><Year>2010</Year><RecNum>753</RecNum><DisplayText><style face="superscript">56</style></DisplayText><record><rec-number>753</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">753</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Carrington, Christine</author><author>Stone, Leanne</author><author>Koczwara, Bogda</author><author>Searle, Christina</author><author>Siderov, Jim</author><author>Stevenson, Ben</author><author>Michael, Michael</author><author>Hyde, Susan</author><author>Booth, Angela</author><author>Rushton, Shelley</author></authors></contributors><titles><title>The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy</title><secondary-title>Asia-Pacific Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Asia-Pacific Journal of Clinical Oncology</full-title></periodical><pages>220-237</pages><volume>6</volume><number>3</number><keywords><keyword>chemotherapy</keyword><keyword>medication error</keyword><keyword>nurse</keyword><keyword>pharmacist</keyword><keyword>prescription</keyword></keywords><dates><year>2010</year></dates><publisher>Blackwell Publishing Asia</publisher><isbn>1743-7563</isbn><urls><related-urls><url> assessment and quality assurance are key elements of safe practice associated with antineoplastic agents. Systems, policies and procedures are necessary to assist the reporting of adverse events, incidents and near misses. Identification of 'error prone' practices may indicate the need for practice modification. ADDIN EN.CITE <EndNote><Cite><Author>Carrington</Author><Year>2010</Year><RecNum>753</RecNum><DisplayText><style face="superscript">56</style></DisplayText><record><rec-number>753</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">753</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Carrington, Christine</author><author>Stone, Leanne</author><author>Koczwara, Bogda</author><author>Searle, Christina</author><author>Siderov, Jim</author><author>Stevenson, Ben</author><author>Michael, Michael</author><author>Hyde, Susan</author><author>Booth, Angela</author><author>Rushton, Shelley</author></authors></contributors><titles><title>The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy</title><secondary-title>Asia-Pacific Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Asia-Pacific Journal of Clinical Oncology</full-title></periodical><pages>220-237</pages><volume>6</volume><number>3</number><keywords><keyword>chemotherapy</keyword><keyword>medication error</keyword><keyword>nurse</keyword><keyword>pharmacist</keyword><keyword>prescription</keyword></keywords><dates><year>2010</year></dates><publisher>Blackwell Publishing Asia</publisher><isbn>1743-7563</isbn><urls><related-urls><url> Guidelines for the Safe Prescribing, Supply and Administration of Cancer Chemotherapy ADDIN EN.CITE <EndNote><Cite><Author>Carrington</Author><Year>2010</Year><RecNum>753</RecNum><DisplayText><style face="superscript">56</style></DisplayText><record><rec-number>753</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">753</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Carrington, Christine</author><author>Stone, Leanne</author><author>Koczwara, Bogda</author><author>Searle, Christina</author><author>Siderov, Jim</author><author>Stevenson, Ben</author><author>Michael, Michael</author><author>Hyde, Susan</author><author>Booth, Angela</author><author>Rushton, Shelley</author></authors></contributors><titles><title>The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy</title><secondary-title>Asia-Pacific Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Asia-Pacific Journal of Clinical Oncology</full-title></periodical><pages>220-237</pages><volume>6</volume><number>3</number><keywords><keyword>chemotherapy</keyword><keyword>medication error</keyword><keyword>nurse</keyword><keyword>pharmacist</keyword><keyword>prescription</keyword></keywords><dates><year>2010</year></dates><publisher>Blackwell Publishing Asia</publisher><isbn>1743-7563</isbn><urls><related-urls><url> is a national document developed to oversee the safe practices associated with management of antineoplastic agents used in the treatment of cancer. This document should be used as a guidance tool to inform local practice and be adapted according to local service needs. To prepare nurses to administer antineoplastic agents, educational programs should include both theoretical and supervised clinical experience. ADDIN EN.CITE <EndNote><Cite><Author>Carrington</Author><Year>2010</Year><RecNum>753</RecNum><DisplayText><style face="superscript">56</style></DisplayText><record><rec-number>753</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">753</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Carrington, Christine</author><author>Stone, Leanne</author><author>Koczwara, Bogda</author><author>Searle, Christina</author><author>Siderov, Jim</author><author>Stevenson, Ben</author><author>Michael, Michael</author><author>Hyde, Susan</author><author>Booth, Angela</author><author>Rushton, Shelley</author></authors></contributors><titles><title>The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy</title><secondary-title>Asia-Pacific Journal of Clinical Oncology</secondary-title></titles><periodical><full-title>Asia-Pacific Journal of Clinical Oncology</full-title></periodical><pages>220-237</pages><volume>6</volume><number>3</number><keywords><keyword>chemotherapy</keyword><keyword>medication error</keyword><keyword>nurse</keyword><keyword>pharmacist</keyword><keyword>prescription</keyword></keywords><dates><year>2010</year></dates><publisher>Blackwell Publishing Asia</publisher><isbn>1743-7563</isbn><urls><related-urls><url> Regular assessment of nurses' competence should occur to ensure theory and practice remains evidence based, and to help prevent errors in administration. ADDIN EN.CITE <EndNote><Cite><Author>Wall</Author><Year>2008</Year><RecNum>754</RecNum><DisplayText><style face="superscript">57</style></DisplayText><record><rec-number>754</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">754</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Wall, A.</author><author>Hansen, G. </author></authors><secondary-authors><author>Gates, R.</author><author>Fink, R. </author></secondary-authors></contributors><titles><title>Tips for administering chemotherapy</title><secondary-title>Oncology nursing secrets: your oncology questions answered by experts you trust</secondary-title></titles><edition>3rd</edition><dates><year>2008</year></dates><pub-location>Missouri</pub-location><publisher>Mosby Elsevier</publisher><urls></urls></record></Cite></EndNote>57Learning activitiesCompletedActivities Access your state or territory policy document guiding practice with antineoplastic agents (examples below), and your own institution's policy and procedure for handling cytotoxic substances.Queensland Workplace Health and Safety Strategy. 2006. Guide for handling cytotoxic drugs and related waste.Workcover NSW. 2008. Cytotoxic drugs and related waste guide WorkSafe Victoria. 2003. Handling Cytotoxic Drugs in the Workplace. SHPA Standards of Practice for the Transportation of Cytotoxic Drugs from Pharmacy DepartmentsCancer Nurses Society of Australia Position Statement on the Minimum Education Requirements for Nurses in the Administration of Anti-Cancer Drugs within the Oncology and Non-Oncology SettingAppraise the current policy and procedures for safe handling of cytotoxic waste in your facility in light of these documents.Outline the key elements of an in-service program for nurses new to cancer control on safe handling of antineoplastic agents and their waste products.Outline the principles of safe practice you would apply when advising a person regarding cytotoxic precautions in their home and community.Discuss strategies used to ensure cytotoxic safety for the following groups and individuals:support staff (i.e. cleaners, orderlies)nurses in specialties other than cancerradiology staffpathology staffaccident and emergency staff.Using a local tool, demonstrate required knowledge and skills for safe practice when there is potential for exposure to antineoplastic agents and cytotoxic waste.Central Venous Access Devices (CVADs) in cancer careCentral venous access devices (CVADs) have become an integral component of delivering intravenous therapy in the specialty field of cancer. CVADs provide reliable venous access over a long period of time and have enhanced the quality of life of people affected by cancer, allowing many to receive ambulatory outpatient care as well as the inpatient setting. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> Nurses are pivotal in facilitating the safe management of individuals with CVADs and decreasing the risk of complications. It is imperative that cancer nurses possess theoretical knowledge and clinical skills regarding: ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> anatomical placementclinical indicationstypes of CVADs and the advantages and disadvantages associated with each devicedevice selection criteriacare and maintenance principles prevention, detection and management of complicationsaccessing and de-accessing of devices applicable to their clinical practice.Anatomical placement for CVADsCVADs are all positioned within the central circulation system. The ideal anatomical placement is in the lower third of the Superior Vena Cava (SVC) near the juncture within the Right Atrium. At this point, the catheter tip is free floating in the lumen of the SVC parallel to the vessel walls. This anatomical placement reduces the risk of thrombosis and infection. Any type of infusate can be infused safely because of the high rate of blood flow returning through the SVC to the right side of the heart, providing adequate haemodilution whilst reducing venous irritation. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> Clinical IndicationsIndications for use of CVADs include: ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> of long term therapiescontinues infusion of antineoplastic agentsadministration ofvesicant antineoplastic agentsparenteral nutritionother hyperosmolar solutions to decrease damage to peripheral veinsapheresis proceduresemergency situations.Types of CVADsDifferent CVADs have unique characteristices and advantanges and disadvantages associated with their use. Management of devices also differs between types. CVADs are able to be classified into three categories:Non – TunnelledCentral Venous Line – Percutaneous Peripherally inserted Central Catheter (PICC)Vascath TunnelledHickman Catheter Totally ImplantedPort-a-cath.Tip configurations include open ended single or multi-lumen devices, valved catheters, for example, Groshong and staggered tips. The tip configuration generally determines the type of solution that is required to lock the device.It is imperative that device selection is discussed by all key stakeholders including the treating doctor, nursing staff, the person affected by cancer and other members of the health care team. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> Nurses need to support individuals to make informed decisions regarding which CVAD is appropriate for their circumstances and their planned treatment regimen. Guidelines do not exist for the appropirate selection of CVADs however the following key factors should be considered: ADDIN EN.CITE <EndNote><Cite><Author>Oncology Nursing Society (ONS)</Author><Year>2008</Year><RecNum>1119</RecNum><DisplayText><style face="superscript">59</style></DisplayText><record><rec-number>1119</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1119</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Oncology Nursing Society (ONS),</author></authors></contributors><titles><title>Putting Evidence into Practice (PEP) resource: chemotherapy induced nausea and vomiting</title></titles><number>02.02.2012</number><dates><year>2008</year></dates><urls><related-urls><url> and duration of therapynumber of blood collections requiredtherapy type, for example; administration of vesicant agentssupportive therapy requirements; for example, total parenteral nutrition or systemic antibioticsneed for peripheral stem cell collection, plasmapheresis and reinfusion of peripheral stem cells or bone marrowindividual preference.Resource linkCancer Nurses Society of Australia. Central Venous Access Devices: Principles of Nursing Practice and Education. ACT: Cancer Nurses Society of Australia:2007.Centre for Healthcare Related Infection Surveillance and Prevention (CHRISP) eviQ Cancer Treatments OnlineLearning activitiesCompletedActivities Identify the common uses for CVADs in your local facility.Develop an in-service program for nurses in your clinical practice setting regarding the various types of CVADs taking into consideration:Characteristics of deviceAdvantagesDisadvantagesManagementDescribe how a Groshong valve works to reduce the risk of catheter occlusion, air embolus and the need for heparin. Draw a picture of the valve system to demonstrate understanding. Insertion of CVADsMany CVADs are now inserted in radiology departments by a radiologist. In some settings, nurses educated and trained in the insertion of PICCs undertake this procedure. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> Conscious sedation is used in many CVAD insertion procedures. Conscious sedation is a drug-induced depression of consciousness during which the person can respond purposefully to verbal commands or tactile stimulation. ADDIN EN.CITE <EndNote><Cite><Author>US Department of Health and Human Services</Author><Year>2010</Year><RecNum>1121</RecNum><DisplayText><style face="superscript">60</style></DisplayText><record><rec-number>1121</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1121</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>US Department of Health and Human Services,</author><author>National Institute of Health (NIH),</author><author>National Cancer Institute (NCI),</author></authors></contributors><titles><title>Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03</title></titles><number>02.02.2012</number><dates><year>2010</year></dates><urls><related-urls><url> of the individual and their carer should commence before the device isinserted and be reinforced regularly. Information provided should include: ADDIN EN.CITE <EndNote><Cite><Author>National Comprehensive Cancer Network (NCCN)</Author><Year>2012</Year><RecNum>1120</RecNum><DisplayText><style face="superscript">61</style></DisplayText><record><rec-number>1120</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1120</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>National Comprehensive Cancer Network (NCCN),</author></authors></contributors><titles><title>NCCN Clinical Practice Guidelines in Oncology: antiemesis. Version 1</title></titles><number>02.02.2012</number><dates><year>2012</year></dates><urls><related-urls><url> rationale, the risks and the benefits of the CVADself management of the CVAD to a level appropriate for their needssigns and symptoms of CVAD related complicationswho to contact if they have concerns and how to contact them.The management of the individual undergoing a procedure to insert a CVAD involves:gaining written consent for the procedure and the sedation (if sedation is planned)preparing the person for the procedure (assessment, fasting, review of pathology, administration of blood products and pre-medications as required).Following catheter insertion, radiological examination (e.g. chest X-ray) shouldbe obtained to: ADDIN EN.CITE <EndNote><Cite><Author>Oncology Nursing Society (ONS)</Author><Year>2008</Year><RecNum>1119</RecNum><DisplayText><style face="superscript">59</style></DisplayText><record><rec-number>1119</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1119</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Oncology Nursing Society (ONS),</author></authors></contributors><titles><title>Putting Evidence into Practice (PEP) resource: chemotherapy induced nausea and vomiting</title></titles><number>02.02.2012</number><dates><year>2008</year></dates><urls><related-urls><url> catheter placement detect adverse eventsprovide record of placement. The anatomical placement of the catheter tip must be documented and checked prior to the initiation of any therapy through the device. ADDIN EN.CITE <EndNote><Cite><Author>Wood</Author><Year>2011</Year><RecNum>1122</RecNum><DisplayText><style face="superscript">62</style></DisplayText><record><rec-number>1122</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wood, Janelle M.</author><author>Chapman, Kathleen</author><author>Eilers, June</author></authors></contributors><titles><title>Tools for assessing nausea, vomiting, and retching</title><secondary-title>Cancer Nursing</secondary-title></titles><periodical><full-title>Cancer Nursing</full-title></periodical><volume>34</volume><number>1</number><dates><year>2011</year></dates><urls></urls></record></Cite></EndNote>62 Learning activitiesCompletedActivities Refer to your local policy and procedures and the CNSA Central Venous Access Devices: Principles of Nursing Practice and Education. Develop a care plan for an individual undergoing a procedure to have a CVAD inserted.Outline the rationale for the following prior to insertion of a CVADAntibioticsPlateletsDescribe the information and supportive care needs of a person and their carer pre insertion of a CVAD and the nursing responses to their needs.You are caring for a person who is having a Hickman tunnelled catheter inserted. He swims daily in the local public pool and asks if he will be able to continue to do this while the Hickman catheter is insitu. What information and advice would you provide to him?Care and maintenance principlesAll facilities caring for people who have a CVAD should have specific evidence based policies and procedures which undergo a robust review and evaluation process. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> The care and maintenance of CVADs differs between facilities. Some areas of CVAD management remain contentious or unclear despite a vast amount of research and debate. These include: ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> appropriate skin antisepticappropriate cleansing of needleless access capsCVAD dressing requirements, i.e type and frequency of changingsecurement devicesflushing techniquesflushing and locking solutions.There are a wide variety of complications that can occur with CVADs. Early identification of problems and prompt management will ensure safety and also preserve the device to ensure ongoing delivery of the individual’s planned treatment regimen. Complications can include: ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> thrombosisair embolisminfiltration and extravasationcardiac tamponadedysrhythmiasCVAD tip migrationcatheter damage.The removal of a CVAD should only be performed by an appropriately educated and trained health care practitioner. If the device is being removed due to suspected or confirmed infection, the tip may be cut off using a sterile procedure and sent for culturing. ADDIN EN.CITE <EndNote><Cite><Author>National Cancer Institute (NCI)</Author><Year>2011</Year><RecNum>1123</RecNum><DisplayText><style face="superscript">63</style></DisplayText><record><rec-number>1123</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1123</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>National Cancer Institute (NCI),</author></authors></contributors><titles><title>Nausea and Vomiting PDQ</title></titles><number>02.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> On removal of the CVAD, the health care practitioner should check the catheter’s integrity and length to ensure removal of the entire device. ADDIN EN.CITE <EndNote><Cite><Author>National Cancer Institute (NCI)</Author><Year>2011</Year><RecNum>1123</RecNum><DisplayText><style face="superscript">63</style></DisplayText><record><rec-number>1123</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">1123</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>National Cancer Institute (NCI),</author></authors></contributors><titles><title>Nausea and Vomiting PDQ</title></titles><number>02.02.2012</number><dates><year>2011</year></dates><urls><related-urls><url> Following removal, digital pressure should be exerted over two sites – the vein insertion area and the exit wound– until haemostasis is achieved. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> Following removal, nurses should monitor the site and implement interventions as required. ADDIN EN.CITE <EndNote><Cite><Author>Cancer Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><DisplayText><style face="superscript">58</style></DisplayText><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> Nurses Society of Australia</Author><Year>2007</Year><RecNum>475</RecNum><record><rec-number>475</rec-number><foreign-keys><key app="EN" db-id="2r0xs09pw9seaee0dd7xtz5mpw90x2t2rape">475</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Cancer Nurses Society of Australia,</author></authors></contributors><titles><title>Central Venous Access Devices: principles for nursing practice and education</title></titles><number>07.07.2011</number><dates><year>2007</year></dates><urls><related-urls><url> activitiesCompletedActivities Appraise current policy and procedures in your facility in light of national and state guidelines (see Resource link) and discuss the variables in practice with your resource person.PICC dressingHickman Catheter DressingPOC accessing and dressing Flushing of CVADsIdentify two contributing factors for the development of catheter related infections.Name two common infective organisms.List three signs and symptoms which would indicate a CVAD infection.Identify clinical practicies undertaken to prevent CVAD infections.You are required to collect a blood sample from a person with a totally implantable CVAD (port-a-cath). When you attempt to aspirate blood you are unsuccessful; however, you are able to flush the catheter. Describe what actions you would take? Identify what the possible reasons may be for your inability to aspirate blood.Describe three types of thrombotic occlusion and how they may arise.Identify how to prevent and manage damage to a CVAD.Access and review the EdCaN Competency Assessment Tool or local competency/skills based assessment tool for Management of CVADs. In collaboration with your education support staff, develop a plan for a period of supervised practice to develop competence in management of CVADs. Use the Comptenency Assessment Tool as a guide for your supervised practice. References ADDIN EN.REFLIST 1.National Breast Cancer Centre, National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown: National Breast Cancer Centre; 2003.2.Supportive Cancer Care Victoria. Facilitator Manual: Supportive Care Screening Communication Skills Case Studies. In: Department of Health, editor. Victoria: Supportive Cancer Care Victoria Project & Victorian Cancer Council; 2011.3.Supportive Cancer Care Victoria. Scenario one: responding to anger. 2012 [15.06.2012]; Available from: Cancer Care Victoria. Scenario two: resonding to emotional cues. 2012 [15.06.2012]; Available from: S, Yates P. A national professional development framework for cancer nursing. 2nd ed. Canberra: Cancer Australia, The National Cancer Nursing Education Project; 2009.6.Psychology Support Working Group. Guidelines for Holistic Needs Assessment of Adult Cancer Patients. Mersyeside and Cheshire Cancer Network; 2010.7.Cancer Institute New South Wales. Immediate management of neutropaenic fever. Cancer Institute of NSW; 2010 [12.05.2011]; Available from: Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: prevention and treatment of cancer-related infections, version 2. 2011 [17.02.2012]; Available from: T. Evidence summary: infection management: febrile neutropaenia. Adelaide: Joanna Briggs Institute; 2011.10.Harnett PR. Oncological emergencies. In: Bishop J, editor. Cancer facts: a concise oncology text. London: CRC Press; 1999.11.Lyman GH, Lyman CH, Agboola O, for the Anc Study Group. Risk Models for Predicting Chemotherapy-Induced Neutropenia. Oncologist. 2005;10(6):427-37.12.Walji N, Chan AK, Peake DR. Common acute oncological emergencies: diagnosis, investigation and management. Postgraduate Medical Journal. 2008;84(994):418-27.13.Daniels R. Defining sepsis, severe sepsis and septic shock. NHS; 2009 [24.03.2011]; Available from: MM. Introduction. In: Daniels R, Nutbeam T, editors. ABC of Sepsis,2009.15.Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine. 2008;36:296-327.16.Hogan DK, Rosenthal LD. Oncologic emergencies in the patient with lymphoma. Seminars in Oncology Nursing. 1998 14(4):312-20.17.eviQ, Cancer Institute New South Wales. eviQ Home. Cancer Institute NSW; [12.05.2011]; Available from: . Tumour lysis syndrome, risk assessment, prophylaxis. Cancer Institute New South Wales; 2010 [02.06.2011]; Available from: SC, Jones DP, Pui C-H. The Tumor Lysis Syndrome. New England Journal of Medicine. 2011;364(19):1844-54.20.Ezzone SA. Tumor lysis syndrome. Seminars in Oncology Nursing. 1999;15(3).21.Doane L. Overview of tumour lysis syndrome. Seminars in Oncology Nursing. 2002;18(3).22.National Institute for Health and Clinical Excellence (NICE). Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. National Collaborating Centre for cancer; 2008.23.Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Journal of Clinical Oncology. 2005;23(9):2028-37.24.eviQ. Radiation oncology, palliation, spinal cord compression (SCC). Cancer Institute New South Wales; 2010 [02.06.2011]; Available from: C, Pollard A, Thomson K, Aranda S. Unmet needs in cancer patients: development of a supportive needs screening tool (SNST). Supportive Care in Cancer. 2009;17(1):33-45.26.National Breast Cancer Centre, National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown, NSW: National Breast Cancer Centre; 2003.27.Continence Foundation of Australia. Continence Foundation of Australia home page. 2010 [07.07.2011]; Available from: J. Superior vena cava syndrome. Emergency medicine clinics of North America. 2009;27(2):243-55.29.Wudel L, Nesbitt J. Superior vena cava syndrome. Current Treatment Options in Oncology. 2001;2(1):77-91.30.Wilson LD, Detterbeck FC, Yahalom J. Superior Vena Cava Syndrome with Malignant Causes The New England Journal of Medicine. 2007;356(18):1862-9.31.Medlibes Online Medical Library. Superior vena cava syndrome. 2010 [03.06.2011]; Available from: M. Disseminated intravascular coagulation. Journal of Coagulation Disorders. 2011;3(1):55-63.33.Plaut D. The Laboratory's Role in Disseminated Intravascular Coagulation. Journal of Continuing Education Topics & Issues. 2011;13(1):24-8.34.Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). ASH Education Program Book. 2009(1):240-6.35.Levi MM, Schmaier AH. Disseminated intravascular coagulation. 2011 [23.02.2012]; Available from: DK. Death by clot: acute coronary syndromes, ischemic stroke, pulmonary embolism, and disseminated intravasucular coagulation. AACN Advanced Critical Care. 2009;20(2):166-76.37.Zhaoyue Wang, Ziqiang Yu, Jian Su, Lijuan Cao, Xiaojuan Zhao, Changgeng Ruan. Sepsis-Induced Disseminated Intravascular Coagulation With Features of Thrombotic Thrombocytopenic Purpura: A Fatal Fulminant Syndrome. Clinical and Applied Thrombosis/Hemostasis. 2011;17(3):251-3.38.Becker JU, Kumar A, Salim Shaaban H, Wira CR. Disseminated intravascular coagulation in emergency medicine. Medscape Reference; 2011 [22.02.2012]; Available from: D, Kara F. Retiform Purpura. New England Journal of Medicine. 2008;358(2):e1.40.Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Journal of Haematology. 2009;145(1):24-33.41.Toh CH, Hoots WK, Ssc On Disseminated Intravascular Coagulation Of The I. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview1. Journal of Thrombosis and Haemostasis. 2007;5(3):604-6.42.Taylor Jr FB, Toh C-H, Hoots WK, Wada H, Levi M. Scientific and Standardizat ion Committee Communications: Towards a Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation on behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis. 2001 [22.02.2012]; Available from: Red Cross Blood Service. Management of DIC. 2010 [23.02.2012]; Available from: M. Nursing management of common oncological emergencies. Nursing Standard. 2010;24(41):49-56.45.Basso U, Roma A, Brunello A. Hypercalcemia and malignancy. In: Lumachi F, Basso SMM, editors. Hypercalcemia pathophysiology and treatment. UAE: Bentham Science; 2010.46.Ralston SH. Management of hypercalcaemia. In: Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G, editors. Textbook of bone metastases: John Wiley and Sons; 2005.47.Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman D, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. Journal of the National Comprehensive Cancer Network (JNCCN). 2009;7(Supplement 7).48.Haas ML, Kuehn EF. Teletherapy: External radiation therapy. In: Watkins-Bruner D, Moore-Higgs G, Haas M, editors. Outcomes in radiation therapy. Boston: Jones & Bartlett; 2001. p. 55-66.49.McQuestion M. Radiation protection and safety. In: Haas M, Hogle GJ, Moore-Higgs G, Gosselin-Acomb TK, editors. Radiation therapy: a guide to patient care. St Louis: Mosby Elsevier; 2007.50.Dunne-Daly C. Principles of brachytherapy. In: Dow KH, Bucholtz JH, Iwamoto R, Fieler V, Hilderley L, editors. Nursing care in radiation oncology. Philadelphia: W.B. Saunders; 1997. p. 21-35.51.Temple SV. Radiopharmaceuticals. In: Haas M, Hogle GJ, Moore-Higgs G, Gosselin-Acomb TK, editors. Radiation therapy: a guide to patient care. St Louis: Mosby Elsevier; 2007.52.Workcover NSW. Cytotoxic drugs and related waste guide. 2008 [28.10.2011]; Available from: Government. Queensland Workplace Health and Safety Strategy. Guide for handling cytotoxic drugs and related waste. 2005 [28.10.2011]; Available from: Victoria. Handling cytotoxic drugs in the workplace. 2003 [28.10.2011]; Available from: M, Whitford J, Olsen N, editors. Chemotherapy and biotherapy guidelines and recommendations for practice. 3rd ed. Philadelphia: Oncology Nursing Society; 2009.56.Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia-Pacific Journal of Clinical Oncology. 2010;6(3):220-37.57.Wall A, Hansen G. Tips for administering chemotherapy. In: Gates R, Fink R, editors. Oncology nursing secrets: your oncology questions answered by experts you trust. 3rd ed. Missouri: Mosby Elsevier; 2008.58.Cancer Nurses Society of Australia. Central Venous Access Devices: principles for nursing practice and education. 2007 [07.07.2011]; Available from: Nursing Society (ONS). Putting Evidence into Practice (PEP) resource: chemotherapy induced nausea and vomiting. 2008 [02.02.2012]; Available from: Department of Health and Human Services, National Institute of Health (NIH), National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010 [02.02.2012]; Available from: Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: antiemesis. Version 1. 2012 [02.02.2012]; Available from: JM, Chapman K, Eilers J. Tools for assessing nausea, vomiting, and retching. Cancer Nursing. 2011;34(1).63.National Cancer Institute (NCI). Nausea and Vomiting PDQ. 2011 [02.02.2012]; Available from: . ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
Related searches
- top 10 professional development goals
- professional development plan template word
- teacher professional development goals e
- teacher professional development goal sheet
- list of professional development goals
- professional development classes for educators
- professional development plan template free
- professional development plan template
- free professional development for teachers
- middle school professional development plan
- online professional development free
- professional development goals examples